WO2000001732A2 - Composes, compositions et procedes destines a la presentation endocytique de facteurs immunosuppresseurs - Google Patents

Composes, compositions et procedes destines a la presentation endocytique de facteurs immunosuppresseurs Download PDF

Info

Publication number
WO2000001732A2
WO2000001732A2 PCT/US1999/015225 US9915225W WO0001732A2 WO 2000001732 A2 WO2000001732 A2 WO 2000001732A2 US 9915225 W US9915225 W US 9915225W WO 0001732 A2 WO0001732 A2 WO 0001732A2
Authority
WO
WIPO (PCT)
Prior art keywords
cell
plp
cells
peptide
fragments
Prior art date
Application number
PCT/US1999/015225
Other languages
English (en)
Other versions
WO2000001732A3 (fr
Inventor
Habib Zaghouani
Original Assignee
The University Of Tennessee Research Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of Tennessee Research Corporation filed Critical The University Of Tennessee Research Corporation
Priority to AU50908/99A priority Critical patent/AU5090899A/en
Priority to CA002331771A priority patent/CA2331771A1/fr
Priority to EP99935427A priority patent/EP1093464A2/fr
Publication of WO2000001732A2 publication Critical patent/WO2000001732A2/fr
Publication of WO2000001732A3 publication Critical patent/WO2000001732A3/fr
Priority to US11/612,773 priority patent/US20070218053A1/en
Priority to US12/346,716 priority patent/US20090280132A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • the present invention generally relates to compounds, compositions and methods for the effective endocytic presentation of immunosuppressive factors. More particularly, the present invention is directed to compounds, methods and compositions comprising immunosuppressive factors that are useful for the treatment of various disorders including, but not limited to, autoimmune disorders.
  • the immunosuppressive factors may be T cell receptor antagonists or agonists.
  • Other embodiments of the invention provide for the induction of tolerance in neonates or infants.
  • Vertebrates possess the ability to mount an immune response as a defense against pathogens from the environment as well as against aberrant cells, such as tumor cells, which develop internally.
  • the immune response is the result of complex interactions between a variety of cells and factors, but generally comprises two main facets.
  • One is a cellular component, in which specialized cells directly attack an offending agent (bearing an antigen) while the other is a humoral component, in which antibody molecules bind specifically to the antigen and aid in its elimination. Acting in concert, the individual elements are quite effective in limiting the initial onslaught of invading pathogens and eliminating them from the host.
  • lymphocytes which generally comprise two principal classes.
  • the first of these, designated B cells or B lymphocytes are typically generated in bone marrow and are, among other duties, responsible for producing and secreting antibodies.
  • B cell antibody products tend to react directly with foreign antigens and neutralize them or activate other components of the immune systems which then eliminate them.
  • opsonizing antibodies bind to extracellular foreign agents thereby rendering them susceptible to phagocytosis and subsequent intracellular killing.
  • T cells or T lymphocytes which generally develop or mature in the thymus, are responsible for mediating the cellular immune response.
  • MHC major histoco patibility complex
  • IgG immunoglobulin G
  • H heavy chain
  • L immunoglobulin light chain
  • V L and V H variable regions
  • ACS antigen combining site
  • Each of the heavy chains also includes a constant region defining a particular isotype and assigns the immunoglobulin to one of the immunoglobulin classes and subclasses.
  • the constant region contains units called domains (i.e. C , C H2 , etc.) which do not vary significantly among antibodies of a single class.
  • the constant region does not participate in antigen binding, but can be associated with a number of biological activities known as "effector functions", such as binding to Fc receptors on cell surfaces of antigen presenting cells (APC's) as well as binding to complement proteins.
  • effector functions such as binding to Fc receptors on cell surfaces of antigen presenting cells (APC's) as well as binding to complement proteins.
  • Antigen presenting cells such as dendritic cells and macrophages are, among other features, generally distinguished by the presence of a Fc receptor.
  • an antibody if an antibody is bound to a pathogen, it can then link to a phagocyte via the Fc portion. This allows the pathogen to be ingested and destroyed by the phagocyte, a process known as opsonization.
  • various pathogenic antigens may be processed and displayed by the APC to further stimulate an immune response.
  • the light chains have a single constant domain (C L ).
  • C L constant domain
  • a light chain pairs with a heavy chain through a disulfide bond which attaches heavy constant region C m to C L .
  • the heavy chains have a hinge region separating constant regions C H1 and C H2 from the remainder of the molecule. It is this hinge region that is largely responsible for the flexibility of the tetramer.
  • the two heavy chains of the molecule pair together through disulfide bonds at the junction between the hinge region and C H2 .
  • immunoglobulin genes have evolved so as permit the production of vast numbers of different immunoglobulin proteins from a finite number of genes i.e. inherent polymorphism. Due to inherent polymorphism, mammals are able to produce antibodies to a seemingly infinite variety of antigens.
  • immunoglobulin genetics and protein structure see Lewin, "Genes III", John Wiley and Sons, N.Y. (1987) and Benjamini and Leskowitz, 1988, Immunology, Alan R. Liss, inc., New York which is incorporated herein by reference. In the past few years antibodies have become extremely important in diagnostic and therapeutic applications due to their diversity and specificity.
  • a single antibody producing B cell can be immortalized by fusion with a tumor cell and expanded to provide an in vitro source of antibodies of a single specificity known as a "monoclonal antibody” (mAb).
  • mAb monoclonal antibody
  • Such an immortal B cell line is termed a "hybridoma.”
  • murine mouse
  • a mouse was typically injected with a selected antigen or im unogen.
  • the animal was sacrificed and cells removed from its spleen were fused with immortal myeloma cells.
  • murine mAb have not proven to be well suited for therapeutic applications in most mammals including humans. In part, this is due to the fact that murine antibodies are recognized as foreign by other mammalian species and elicit an immune response which may itself cause illness or undesirable side effects.
  • humanized chimeric immunoglobulin molecules which contain the antigen binding complementarity determining regions of the murine antibodies but in which the remainder of the molecule is composed of human antibody sequences which are not recognized as foreign.
  • Such antibodies have been used to treat tumors as the mouse variable region recognizes the tumor antigen and the humanized portion of the molecule is able to mediate an immune response without being rapidly eliminated by the body. See, for example, Jones et al.. Nature, 321:522-525 (1986) which is incorporated herein by reference.
  • T lymphocytes or T cells which arise from precursors in the bone marrow, are central players in the immune response against invading viruses and other microbes.
  • the progenitor stem cells migrate to the thymus where, as so-called thymocytes, they become specialized. In particular, they begin to display the receptor molecules that later enable mature T cells to detect infection.
  • T cells must be able to attach through their receptors to microbial antigens (protein markers signaling an invader's presence).
  • microbial antigens protein markers signaling an invader's presence
  • they should be blind to substances made by the body as self-reactive T cells can destroy normal tissues.
  • Typically, only those thymocytes that make useful receptors will mature fully and enter the bloodstream to patrol the body. Others that would be ineffectual or would attack the body's own tissue are, in healthy individuals, eliminated through apoptosis prior to leaving the thymus.
  • Mature T cells that finally enter the circulation remain at rest unless they encounter antigens that their receptors can recognize. Upon encountering the specific antigens for which the lymphocytes have affinity, they proliferate and perform effector functions, the result of which is elimination of the foreign antigens.
  • T cells have been classified into several subpopulations based on the different tasks they perform. These subpopulations include helper T cells (T h ), which are required for promoting or enhancing T and B cell responses; cytotoxic (or cytolytic) T lymphocytes (CTL), which directly kill their target cells by cell lysis; and suppressor T cells (T s ) which down-regulate the immune response.
  • T h helper T cells
  • CTL cytotoxic (or cytolytic) T lymphocytes
  • T s suppressor T cells
  • the T cells recognize antigens, but only when presented on the surface of a cell by a specialized protein complex attached to the surface of antigen presenting cells.
  • T cells use a specific receptor, termed the T cell antigen receptor (TCR), which is a transmembrane protein complex capable of recognizing an antigen in association with the group of proteins collectively termed the major histocompatibility complex (MHC).
  • TCR T cell antigen receptor
  • MHC major histocompatibility complex
  • Thousands of identical TCR's are expressed on each cell.
  • the TCR is related, both in function and structure, to the surface antibody (non-secreted) which B cells use as their antigen receptors.
  • different subpopulations of T cells also express a variety of cell surface proteins, some of which are termed "marker proteins" because they are characteristic of particular subpopulations. For example, most T h cells express the cell surface CD4 protein, whereas most CTL and T s cells express the cell surface CD8 protein.
  • markers proteins are important in the initiation and maintenance of immune responses which depend on the recognition of, and interactions between, particular proteins or protein complexes on the surface of APCs.
  • MHC major histocompatibility complex
  • the structures are of two types: class I MHC which displays peptides from proteins made inside the cell (such as proteins produced subsequent to viral replication), and class II MHC, which generally displays peptides from proteins that have entered the cell from the outside (soluble antigens such as bacterial toxins). Recognition of various antigens is assured by inherited polymorphism which continuously provides a diverse pool of MHC molecules capable of binding any microbial peptides that may arise.
  • nucleated cells produce and express class I MHC which may exhibit naturally occurring peptides, tumor associated peptides or peptides produced by a viral invader.
  • lymphoid cells those generally known as antigen presenting cells, produce and express class II MHC proteins.
  • both classes of MHC carry peptides to the cell surface and present them to resting T lymphocytes.
  • T h cells recognize class II MHC- antigen complexes while CTL's tend to recognize class I MHC-antigen complexes.
  • TCR When a resting T cell bearing the appropriate TCR encounters the APC displaying the peptide on its surface, the TCR binds to the peptide-MHC complex. More particularly, hundreds of TCR's bind to numerous peptide-MHC complexes. When enough TCRs are contacted, the cumulative effect activates the T cell.
  • Receptors on T cells that are responsible for the specific recognition of, and response to, the MHC-antigen complex are composed of a complex of several integral plasma membrane proteins. As with the MHC complex previously discussed, a diverse pool of TCR's is assured by inherent polymorphism leading to somatic rearrangement. It should be emphasized that, while the pool of TCR's may be diverse, each individual T cell only expresses a single specific TCR. However, each T cell typically exhibits thousands of copies of this receptor, specific for only one peptide, on the surface of each cell. In addition, several other types of membrane associated proteins are involved with T cell binding and activation.
  • Activation of the T cell entails the generation of a series of chemical signals (primarily cytokines) that result in the cell taking direct action or stimulating other cells of the immune system to act.
  • CTL's proliferate and act to destroy infected cells presenting the same antigen. Killing an infected cell deprives a virus of life support and makes it accessible to antibodies, which finally eliminate it.
  • activation of T h cells by class II MHC-antigen complexes does not destroy the antigen presenting cell (which is part of the host's defense system) but rather stimulates the T h cell to proliferate and generate signals (again primarily cytokines) that affect various cells.
  • the signaling leads to B cell stimulation, macrophage activation, CTL differentiation and promotion of inflammation. This concerted response is relatively specific and is directed to foreign elements bearing the peptide presented by the class II MHC system.
  • the immune response When operating properly the immune response is surprisingly effective at eliminating microscopic pathogens and, to a lesser extent, neoplastic cells.
  • the complicated mechanisms for self-recognition are very efficient and allow a strong response to be directed exclusively at foreign antigens.
  • the immune system occasionally malfunctions and turns against the cells of the host thereby provoking an autoimmune response.
  • autoimmunity is held to occur when the antigen receptors on immune cells recognize specific antigens on healthy cells and cause the cells bearing those particular substances to die.
  • autoimmune reactions are self-limited in that they disappear when the antigens that set them off are cleared away.
  • the autoreactive lymphocytes survive longer than they should and continue to induce apoptosis or otherwise eliminate normal cells.
  • T cell-APC interactions dictates thymic learning and tolerance to self antigens. Accordingly, high avidity interactions lead to elimination of the T cell whereas low avidity interactions allow for maturation and exit from the th ⁇ mus. Although this mechanism is effective in purging the immune system of autoreactivity, T cell precursors endowed with self reactivity could still be generated and migrate to the periphery if the autoantigen is sequestered and does not achieve effective levels of thymic presentation, is subjected to thymic crypticit ⁇ , or is poorly presented.
  • superantigens capable of reacting with particular T cell receptors and events that could stimulate antigen mimicry, epitope spreading or peripheral loosening in peptide crypticity may trigger activation of those self-reactive T cells and cause antigen exposure.
  • continuous supply of autoantigen and abundant generation of T cell receptor ligands are a likely mechanism of T cell aggressivity.
  • Examples of such a spontaneous break in self-tolerance include multiple sclerosis (MS), rheumatoid arthritis (possibly more than one mechanism) and type I diabetes all of which are thought to be T cell mediated autoimmune diseases.
  • multiple sclerosis is a chronic, inflammatory disorder that affects approximately 250,000 individuals in the United States.
  • the inflammatory process occurs primarily within the white matter of the central nervous system and is mediated by T cells, B cells and macrophages which are responsible for the demyelination of the axons.
  • T cells T cells
  • B cells macrophages which are responsible for the demyelination of the axons.
  • the most common form is manifested by relapsing neurological deficits including paralysis, sensory deficits and visual problems.
  • T cells are targeted to certain key portions of various myelin antigens such as those presented on myelin basic protein (MBP) and proteolipid protein (PLP).
  • MBP myelin basic protein
  • PBP proteolipid protein
  • the T cells in turn produce cytokines which then influence macrophages to attack the myelin and phagocytose large chunks of the myelin sheath.
  • the concerted attack leads to areas of demyelination impairing salutary conduction along the axon and producing and the pathoph ⁇ siologic defect.
  • autoimmune diseases have met with varying levels of success. For example, it is often possible to correct organ-specific autoimmune disease through metabolic control. Where function is lost and cannot be restored, mechanical substitutes or tissue grafts may be appropriate. However, no effective treatments exist for several of the most disabling disorders including MS. While a number of compounds, including corticosterioids and modified beta interferon, can reduce some symptoms of MS, they have proven to have serious side effects or otherwise been shown to be less than desirable for long term use. Other avenues of treatment have shown promise but have yet to be shown effective.
  • WO 96/16086 discloses the use of peptide analogs of myelin basic protein (MBP).
  • MBP myelin basic protein
  • Compositions comprising these analogs are reportedly able to ameliorate symptoms of MS without excessive side effects.
  • use of peptide analogs to myelin constitutive proteins were also shown to be effective in treating the symptoms of experimental allergic encephalomyelitis (EAE), an organ specific immune disorder often used in mice as a model for MS.
  • EAE allergic encephalomyelitis
  • PLP proteolipid
  • free peptides typically have very short half-lives, they are not readily incorporated and processed by the MHC- antigen presenting system, little will be naturally expressed on the APC. Due to the inefficient presentation, direct inhibition of the thousands of TCR's on each T cell likely require prohibitively high intracellular levels of free peptide.
  • the turnover of cell surface MHC molecules also contributes to the short stay of complexes formed at the extracellular milieu (i.e. MHC class II molecules have been in the cell surface for some time before binding the extracellular peptide) while complexes formed in the endocytic compartment will reside for a normal period of time because they have just been translocated to the cell surface.
  • the methods and associated compounds and compositions of the present invention which, in a broad aspect, provides for an Fc receptor mediated, endocytic delivery system.
  • the invention provides for the effective presentation of immunosuppressive factors which, in preferred embodiments, may comprise T ceil receptor antagonists or agonists.
  • immunosuppressive factors comprising one or more autoantigenic polypeptides or fragments thereof. That is, the present invention generally provides methods, compounds and compositions to present immunosuppressive factors for the selective modification of an immune response in a vertebrate.
  • the invention provides for Fc receptor mediated endocytic presentation of one or more selected T cell receptor antagonists or agonists to modulate an immune response mounted against a specific antigen.
  • the disclosed methods and compositions may be used to treat any physiological disorder related to the immune response of a vertebrate.
  • this ability to suppress selected components of the immune system may allow, among other things, for the treatment of autoimmune diseases, facilitation of tissue or organ transplants and the mitigation of symptoms produced by allergens.
  • the present invention further provides for the induction of tolerance in neonates and infants with regard to autoantigens.
  • the endocytic presentation of the selected immunosuppressive factor is facilitated through the use of an immunomodulating agent that is able to bind to the Fc receptor (FcR) of antigen presenting cells.
  • the immunomodulating agent will comprise at least one immunosuppressive factor associated with at least one ligand capable of binding to a Fc receptor.
  • APC antigen presenting cell
  • the internalized immunosuppressive factor which can be part or all of an autoantigenic polypeptide or a T cell receptor antagonist or agonist, will then be associated with the newly synthesized endogenous MHC class II structures and presented at the surface of the APC.
  • the immunosuppressive factors can be part or all of an autoantigenic polypeptide or a T cell receptor antagonist or agonist.
  • TCR antagonists or agonists can prevent a previously primed T cell (i.e. one sensitized to a particular autoantigen) from activating and triggering an immune response despite normal presentation of the naturally occurring autoantigen.
  • the immunomodulating agents of the present invention may comprise any ligand (FcR ligand) that is capable of binding to, and being internalized by, the Fc receptor of an antigen presenting cell.
  • the FcR ligand may be any protein, protein fragment, peptide or molecule that effectively binds to a Fc receptor on the surface of any antigen presenting cell.
  • the FcR ligand will comprise or mimic at least some portion of a constant region of an immunoglobulin molecule and will not provoke an antigenic response in the subject.
  • the FcR ligand will comprise part or all of a constant region from an IgG molecule.
  • FcR ligands comprising the entire constant region of a selected immunoglobulin molecule from the species to be treated.
  • binding to the Fc receptor may also be effected by ligands that comprise small fragments of a single constant region domains or non amino acid based molecular entities.
  • the FcR ligand may be derived using modern pharmaceutical techniques such as directed evolution, combinatorial chemistry or rational drug design.
  • the compounds of the present invention further comprise an immunosuppressive factor associated with the FcR ligand to provide an immunomodulating agent.
  • the immunosuppressive factor can be any molecular entity that is capable of being processed by an APC and presented in association with class II MHC molecules on the cell surface.
  • selected embodiments of the invention comprise associating at least one T cell receptor antagonist or agonist with an FcR ligand for efficient presentation via Fc mediated uptake.
  • the immunosuppressive factor may comprise one or more selected autoantigenic polypeptides, or fragments thereof, which can be processed (i.e. digested or proteolyzed) to provide the desired TCR agonists.
  • the autoantigenic pol ⁇ peptide(s), or fragments thereof will provide more than one peptide agonist (i.e.
  • the present invention employs immunosuppressive factors comprising all or part of a T cell antagonist.
  • the term "antagonist” shall, in accordance with its normal meaning, comprise any substance that interferes with the physiological action of another by combining with, and blocking, its receptor.
  • TCR antagonists are molecular entities that, in combination with class
  • the TCR antagonist comprises a peptide or protein fragment that is an analog of the normal activating antigen agonist.
  • the TCR antagonist is an analog of a T cell epitope.
  • the immunosuppressive factor may comprise a T cell agonist that is presented but which does not activate primed TCRs upon binding.
  • TCR agonist constructs or agonist producing autoantigenic polypeptide constructs will preferably take place using a carrier lacking an adjuvant (such as saline).
  • adjuvant such as saline
  • the term "agonist” shall be used in accordance with its commonly accepted biochemical meaning.
  • the T cell agonist may be any molecule that provides the desired immunogenic result
  • the selected agonist will preferably comprise a peptide or protein fragment.
  • immunomodulating agents comprising one or more T cell receptor agonists may be combined with immunomodulating agents comprising one or more T cell receptor antagonists to provide pharmaceutical formulations that may be used to selectively attenuate a patient's immune response.
  • the ultimately presented TCR agonists may be derived from an immunosuppressive factor that includes all or part of one or more autoantigenic polypeptides. That is, the constructs of the present invention may preferably comprise an FcR ligand associated with one or more autoantigenic polypeptides, or fragments thereof. Typically the incorporated autoantigenic polypeptide(s) or fragments will comprise the wild type amino acid sequence and, when processed (i.e. proteolyzed) following FcR mediated uptake, will provide one or more TCR agonists for presentation by professional or non professional APCs.
  • the administration of such constructs in accordance with the present invention is particularly advantageous as it may be used to overcome difficulties with epitope spreading.
  • a construct of the present invention could take the form of a fusion or chimeric protein comprising the entire Fc region of an IgG molecule covalently linked to natural myelin basic protein (MBP) or natural proteolipid protein (PLP).
  • MBP myelin basic protein
  • PGP natural proteolipid protein
  • fusion proteins compatible with the present invention may comprise the Fc region of IgG covalently linked to an immunosuppressive factor comprising the covalently attached natural forms of PLP and MBP (i.e. IgGFc-MBP-PLP).
  • immunosuppressive factor comprising the covalently attached natural forms of PLP and MBP (i.e. IgGFc-MBP-PLP).
  • IgGFc-MBP-PLP immunosuppressive factor
  • Such constructs will be internalized via the FcR and endocytically processed (proteolyzed with the resulting agonist fragments associated with MHC complexes) and presented on the surface of the APCs.
  • the administration of the FcR ligand / autoantigen constructs induces anergy rather than stimulating an immune response.
  • selected fragments or portions of the naturally occurring autoantigenic polypeptides could be used to form compatible immunosuppressive factors.
  • fusion or chimeric proteins may easily be constructed using modern molecular biology techniques.
  • the FcR ligand is associated with the immunosuppressive factor to form an immunomodulating agent so that both are internalized by the APC at substantially the same time.
  • this association may be in the form of two or more molecules bound to each other as with an antibody- antigen complex or, in preferred embodiments, may comprise the formation of a single fusion or chimeric molecule incorporating both the immunosuppressive factor (i.e. one or more autoantigenic polypeptides or fragments thereof or a
  • TCR antagonist or agonist TCR antagonist or agonist
  • FcR ligand FcR ligand
  • a selected TCR antagonist could be chemically linked to an FcR ligand region produced by proteol ⁇ tic techniques (i.e. an Fc fragment).
  • Other embodiments may comprise a normal immunoglobulin comprising an FcR ligand stericall ⁇ bound to an antagonistic or agonistic peptide.
  • Particularly preferred embodiments of the invention comprise chimeric immunoglobulins produced through genetic engineering techniques.
  • the FcR ligand (and usually the majority of the molecule) comprises one or more immunoglobulin constant regions while one or more of the variable regions is engineered to express one or more desired peptide TCR antagonists or TCR agonists.
  • any combination of the aforementioned immunomodulating agents may be associated to form compositions of the present invention as can similar immunomodulating agents comprising different immunosuppressive factors.
  • mixtures or "cocktails" of various immunomodulating agents are specifically contemplated as falling within the scope of the present invention.
  • the immunomodulating agent or agents may be immobilized or aggregated to provide constructs or structures that advantageously induce the production of anti-inflammatory cytokines such as IL-10 and IL-6. Treatment with aggregated immunomodulating agents may also lead to upregulation of other cytokines such as IL-4, IL-9, IL-13, TGF- ⁇ .
  • cytokines such as IL-10 and IL-6.
  • the desired aggregated or immobilized immunomodulating agents may be fabricated using any one of a number of well known techniques.
  • the immunomodulating agents of the present invention may be chemically associated with microspheres or microparticles (e.g. latex, albumin, PVP or methacrylate microparticles) or immobilized in an easily administered polymer matrix.
  • the immunomodulating agents may be chemically or thermodynamically linked or altered to form soluble or insoluble aggregates.
  • compositions may be formulated using conventional pharmaceutical techniques and carriers and may be administered through the usual routes.
  • Particularly preferred embodiments comprise the use of formulations or carriers that do not comprise adjuvants.
  • Those skilled in the art will appreciate that such preparations avoid or minimize the generation of costimulatory molecules that may provoke an immune response.
  • the use of FcR mediated uptake of the immunomodulating agent avoids many of the problems associated with prior art compositions. More specifically, the methods of the present invention overcome many of the limitations associated with the administration of free peptide antagonists as disclosed in the prior art. Accordingly, efficient endocytic presentation of an immunosuppressive factor such as a TCR antagonist can generate significant levels of MHC-antagonist ligands to oppose naturally occurring MHC-autoantigenic complexes that are generated in spontaneous immune disorders involving the continuous presentation of an autoreactive antigen. Similarly, the efficient uptake of FcR ligand-agonist (or autoantigenic polypeptide) constructs and subsequent presentation of the desired agonist(s) may induce anergy in autoreactive T cells.
  • an immunosuppressive factor such as a TCR antagonist
  • the invention may be used to treat any immune disorder that responds to the presentation of immunosuppressive factors.
  • T cell mediated autoimmune disorders including, for example, multiple sclerosis, lupis, rheumatoid arthritis, scleroderma, insulin-dependent diabetes and ulcerative colitis
  • the present invention can be used to selectively down-regulate the immune system with respect to continuously presented agonists such as allergens.
  • the compounds and associated compositions of the present invention may be used to selectively suppress various components of the immune system to reduce the likelihood of tissue or organ rejection following transplant.
  • the compounds, compositions, and methods of the present invention may be used to induce tolerance to various autoantigens in neonates and infants. More particularly, the present invention further provides compositions and methods for conferring resistance in neonate or infant mammals to the induction of an autoimmune disease during adult life. In accordance with the teachings herein, this neonatal tolerance is characterized by a lymph node deviation and unusual gamma interferon-mediated splenic anergy upon challenge with the appropriate autoantigen. As discussed above, preferred embodiments the present invention may provide for the induction of the desired neonatal tolerance upon administration in a non-reactive carrier (i.e. those without adjuvants).
  • a non-reactive carrier i.e. those without adjuvants
  • Figs. 1A and 1 B are schematic representations of chimeric immunoglobulin G (IgG) molecules illustrating the general features thereof and the inclusion of foreign peptides within the CDR 3 loop of the heavy chain variable region
  • Fig. 1A Ig-PLPl
  • Fig. 1 B Ig-PLP-LR
  • PLP-LR an immunomodulating agent comprising the inclusion of a peptide analog (antagonist) to PLP1 termed PLP-LR;
  • Figs. 2A and 2B are graphical representations illustrating the capture of chimeric antibodies Ig-PLPl and Ig-PLP- LR, which correspond to those shown in Figs. 1A and 1 B respectively, using antibodies directed to the corresponding free peptides wherein Fig. 2A shows capture levels by antibodies directed to PLP1 and Fig. 2B shows capture levels by antibodies directed to PLP-LR with Ig-W, a wild type antibody, acting as a negative control; Figs. 3A and 3B are graphs illustrating the presentation of Ig-PLPl and Ig-PLP-LR (as well as positive and negative controls) to PLP1 -specific T cell hybridomas 4E3 (Fig. 3A) and 5B6 (Fig. 3B) to determine the relative T cell activation potentials of the chimeric immunoglobulins as measured by IL-2 production;
  • Fig. 4 is a graphical representation illustrating the relative effectiveness of presenting PLP1 using the chimeric antibodies of the present invention (Ig-PLPl) versus the free peptide PLP1 or the native proteolipid protein (PLP) as measured by levels of IL-2 production following incubation with splenic SJL antigen presenting cells and PLP1 specific 4E3
  • T cell hybridoma T cell hybridoma
  • Figs. 5A, 5B and 5C are graphical comparisons showing Ig-PLP-LR antagonism of PLP1 (5A), lg-PLP1 (5B) and PLP (5C) mediated T cell activation as measured by IL-2 production by T cell hybridoma 4E3 in the presence of SJL splenic APCs that were previously incubated with the respective agonist and various levels of Ig-PLP-LR or controls; Fig.
  • FIG. 6 is a graph showing the relative antagonism of lg-PLP2, Ig-PLP-LR and Ig-W as measured by the production of IL-2 by T cell hybridoma HT-2 in the presence of SJL splenic APCs that were previously incubated with native proteolipid protein in combination one of the aforementioned immunoglobulins;
  • Figs. 7A and 7B are graphs demonstrating the /; vivo presentation of PLP1 following inoculation with Ig-PLPl as measured by 3 H-thymidine incorporation by cells from the lymph node (7A) or the spleen (7B) wherein the illustrated values represent the ability of cells harvested from individual mice to generate a T cell response as measured by 3 H-thymidine incorporation when exposed to agonist PLP1 or the control peptide PLP2;
  • Figs. 8A and 8B are graphical representations showing the ability of Ig-PLP-LR to reduce the immune response to PLP1 peptide when co-administered with Ig-PLPl as measured in murine cells from the lymph node (8A) or the spleen (8B) wherein the illustrated values represent the ability of cells harvested from individual mice to generate a T cell response as measured by 3 H-thymidine incorporation when exposed to PLP1;
  • Figs. 9A and 9B are graphs demonstrating that mice inoculated with a mixture of Ig-PLP-LR and Ig-PLPl develop a more vigorous immune response to the peptide analog PLP-LR than peptide PLP1 as measured in cells from the lymph node (9A) or the spleen (9B) wherein the illustrated values represent the ability of cells harvested from individual subjects to generate a T cell response as reflected by 3 H-thymidine incorporation when exposed to either PLP1 peptide or the peptide analog PLP-LR;
  • Figs. 10A-10D are graphical representations of lymph node proliferative responses to immunization with Ig-PLP chimeras with mice individually tested in triplicate wells for each stimulator and where the indicated cpms represent the mean ⁇ SD after deduction of background cpms;
  • Fig. 11 is a graphical representation of lymph node T cell proliferative response to co-immunization with Ig-PLPl and Ig-PLPLR with stimulators comprising PPD, 5 mg/ml; PLP 1, PLP-LR, and PLP2 at 15 mg/ml;
  • Fig. 12 is a graphical representation of splenic proliferative T cells responses of mice immunized with Ig-W, Ig- PLPl, IG-PLP-LR and combinations thereof when stimulated with PLP1 (filled bars) and PLP-LR (hatched bars) in triplicate wells;
  • Figs. 13A-13C are graphical representations of IL-2 (13A), INFg (13B), and IL-4 (13C) production by splenic cells of mice immunized with Ig-W, Ig-PLPl, Ig-PLP-LR and combinations thereof;
  • Figs. 14A-14D graphically illustrate proliferation of antigen experienced T cells from mice immunized with Ig- PLPl (a and b) or Ig-PLP-LR (c and d) in CFA upon stimulation in vitro with PLPI peptides, PLP-LR peptides and mixtures thereof;
  • Figs. 15A and 15B are graphical representations of IL-2 production by antigen experienced T cells immunized with Ig-PLPl (15A) and Ig-PLP-LR (15B) upon in vitro stimulation with PLP1 peptide, PLP-LR peptide or mixtures thereof;
  • Figs. 16A and 16B graphically illustrate that neonatal mice injected with Ig-PLPl and Ig-W resist induction of EAE with clinically derived curves shown for all mice (16A) and for surviving mice (16B);
  • Figs. 17A and 17B graphically show in vivo presentation of Ig-PLPl by neonatal thymic (17A) and splenic (17B) antigen presenting cells following injection with Ig-PLPl or Ig-W within 24 hours of birth;
  • Figs. 18A and 18B graphically illustrate lymph (18A) and splenic (18B) proliferative T cell response in mice injected with Ig-PLPl or Ig-W shortly after birth upon stimulation with free PLP1, PLP2 or a negative control peptide corresponding the encephalitogenic sequence 178-191 of PLP;
  • Figs. 19A-19C graphically represent lymph node T cell deviation as measured by production of IL-2 (19A), IL-4 (19B), and INFg (19C) in mice treated with lg-PLP1 shortly after birth and stimulated with free PLP1 or PLP2;
  • Figs. 20A-20C graphically represent splenic T celi deviation as measured by production of IL-2 (20A), IL-4 (20B), and INFg (20C) in mice treated with Ig-PLPl shortly after birth and stimulated with free PLP1 or PLP2;
  • Fig. 21 graphically illustrates cytokine mediated restoration of splenic T cell proliferation in mice injected with Ig-
  • Fig. 22 illustrates that the administration of aggregated Ig-PLPl effectively ameliorates EAE in mice as shown by clinical grading of the condition over an extended period
  • Figs. 23A and 23B shows that incubation of aggregated Ig-PLPl with purified APCs advantageously induces production of anti-inflammatory cytokines IL-6 (23A) and IL-10 (23B).
  • the present invention provides compounds, compositions and methods for selectively modifying the immune response of a vertebrate using an Fc receptor mediated endocytic delivery system.
  • any immunomodulating agent that can exploit this form of cellular uptake to down-regulate the immune system is held to constitute part of the present invention.
  • the immunomodulating agents of the invention may comprise chimeric or fusion polypeptides, antigen-antibody complexes, chimeric antibodies or non-peptide based immunoactive compounds.
  • the immunomodulating compounds disclosed herein will comprise at least one FcR ligand and at least one immunosuppressive factor that is capable of down-regulating an immune response upon endocytic presentation.
  • Particularly preferred embodiments of the invention comprise an immunomodulating agent wherein the immunosuppressive factor is one or more T cell receptor antagonists or agonists that, following endocytic processing and presentation, is capable of binding with a receptor on the surface of a primed T cell but not capable of generating an immunogenic response.
  • the presented immunosuppressive factor will prevent the activation of the relevant primed T cells and reduce the response generated.
  • This selective suppression of the immune system may, among other indications, be used to treat symptoms associated with immune disorders, including T cell mediated autoimmune disorders, allergies and tissue rejection in transplant operations.
  • the present invention comprises an immunomodulating agent for the endocytic presentation of an immunosuppressive factor on the surface of an antigen presenting cell of a vertebrate comprising at least one Fc receptor ligand and at least one immunosuppressive factor.
  • Preferred embodiments comprise a Fc receptor ligand corresponding to at least a part of an immunoglobulin constant region domain while the immunosuppressive factor corresponds to at least one T cell receptor antagonist.
  • Other preferred embodiments incorporate an immunosuppressive factor comprising a T cell receptor agonist.
  • the immunosuppressive factor may comprise one or more autoantigenic polypeptides, or fragments thereof, that provide one or more TCR agonists upon endocytic processing and presentation.
  • the immunomodulating agent comprises a recombinant polypeptide or a chimeric antibody.
  • the present invention By exploiting FcR mediated uptake of the selected immunomodulating agent the present invention very cleverly uses the body's own metabolic pathways to down-regulate harmful immune responses. More specifically, the present invention uses the fact that T cells recognize and respond to foreign antigens when attached to the surface of other cells. Selection of the appropriate immunomodulating agent or agents in accordance with the teachings herein provides for the efficient uptake of the administered compound. Following FcR mediated uptake, the natural endocytic pathway of antigen presenting cells provides for the effective presentation of the selected immunosuppressive factor complexed with the MHC class II molecules.
  • the two requisite properties that allow a cell to function as an antigen presenting cell for class II MHC-restricted helper T cell lymphocytes are the ability to process endocytosed antigens and the expression of class II MHC gene products.
  • Most cells, including professional and nonprofessional APCs appear to be able to endocytose and process protein antigens. Accordingly, with regard to professional APCs the determining factor appears to be the expression of class II MHC molecules.
  • the best defined antigen presenting cells for helper T lymphocytes comprise mononuclear phagocytes, B lymphocytes, dendritic cells, Langerhans cells of the skin and, in some mammals, endothelial cells.
  • different cells may be concentrated in different areas and may be involved in different stages of the T cell mediated immune response.
  • the term "professional antigen presenting cell” or “professional APC” as used herein shall be held to mean any cell capable of inducing a T cell mediated immune response through the processing and surface presentation of an MHC class ll-antigen complex.
  • nonprofessional APCs typically comprise MHC class I presentation complexes.
  • both types of cells may be used to present the selected immunosuppressive factors and down-regulate the immune system.
  • the selected FcR ligand may interact with any of a number of different Fc receptors found on a variety of cell types to promote endocytosis of the immunomodulating agent.
  • FcR ligands may comprise, but are not limited to, peptides, proteins, protein derivatives or small molecular entities that may or may not incorporate amino acids.
  • small molecules derived using modern biochemical techniques such as combinatorial chemistry or rational drug design may be employed as long as they provide for the requisite APC uptake.
  • the FcR ligands of the present invention will preferably comprise one or more peptides. More preferably, the FcR ligand will comprise at least a part of a domain of a constant region of an immunoglobulin. In particularly preferred embodiments the FcR ligand will comprise one or more domains derived from a constant region of an immunoglobulin molecule. Those skilled in the art will appreciate that various immunoglobulin isotypes and allotypes may be employed as desired. For example, compatible FcR ligands may be selected from amino acid sequences corresponding to those found in the constant regions of IgG, IgE, IgA or IgM.
  • selection of a particular isotype for use as a FcR ligand may be predicated on biochemical properties such as binding coefficients or low immunoreactivity in the species to be treated.
  • selection of a single domain, fragment thereof or multiple domains may be determined based on biochemical factors or, ultimately, presentation efficiency.
  • the immunomodulating agents of the present invention further comprise an immunosuppressive factor.
  • the immunosuppressive factor may be any compound that, when endocytically processed and presented on the surface of an APC, will down-regulate the immune system.
  • immunosuppressive factors may comprise small molecules, peptides, protein fragments, protein derivatives, polypeptides or combinations thereof.
  • the immunosuppressive factor acts as an antagonist when presented on the surface of the APC in that it interferes with the binding of a similarly presented agonist to a selected receptor.
  • the immunosuppressive factor comprises a T cell receptor antagonist that will associate with a T cell receptor without activating an immune response.
  • embodiments of the invention comprise immunomodulating agents incorporating T cell receptor agonists that reduce the immune response to the subject autoantigen.
  • Fc mediated presentation of naturally occurring autoantigenic polypeptides may be used to provide the desired T cell receptor agonists via endocytic processing. That is, the administration of naturally occurring autoantigenic polypeptides, or fragments thereof, associated with a FcR ligand results in the efficient presentation of one or more T cell receptor agonists in accordance with the teachings herein.
  • any functionally compatible molecule may be used as an immunosuppressive factor in accordance with the present invention
  • proteins polypeptides
  • protein fragments or peptides are particularly suitable for use in the disclosed compounds and methods.
  • Such molecules are readily processed by the normal endocytic pathways and are easily presented, for example in concert with the MHC class II molecules, on the surface of the antigen presenting cell.
  • T cell receptors are usually most responsive to similar fragments whether they are agonists or antagonists.
  • antagonistic immunosuppressive factors will be analogs of a selected peptide or protein fragment that is immunoreactive with a chosen T cell receptor.
  • Protein analogs or “analogs,” as used herein, contain at least one different amino acid in the respective corresponding sequences between the analog and the native protein fragment or peptide. Unless otherwise indicated a named amino acid refers to the L-form.
  • An L-amino acid from the native peptide may be altered to any other one of the 20 L-amino acids commonly found in proteins, any one of the corresponding D-amino acids, rare amino acids, such as 4- hydroxyprofine, and h ⁇ drox ⁇ lysine, or a non-protein amino acid, such as B-alanine and homoserine.
  • amino acids which have been altered by chemical means such as methylation (e.g., a- methylvaline), amidation of the C-terminal amino acid by an alkylamine such as ethylamine, ethanolamine, and ethylene diamine, and acylation or methylation of an amino acid side chain function (e.g., acylation of the epsilon amino group of lysine).
  • methylation e.g., a- methylvaline
  • alkylamine such as ethylamine, ethanolamine, and ethylene diamine
  • acylation or methylation of an amino acid side chain function e.g., acylation of the epsilon amino group of lysine
  • MS multiple sclerosis
  • PCT Publication No.: WO 96/16086 which has previously been incorporated into the instant application by reference.
  • the disclosed methods may be used in concert with the present invention to provide effective immunosuppressive factors for incorporation in the disclosed immunomodulating agents.
  • candidate peptide analogs may be screened for their ability to treat MS by an assay measuring competitive binding to MHC, T cell proliferation assays or an assay assessing induction of experimental encephalo yelitis (EAE).
  • immunosuppressive factors comprise analogs of T cell epitopes. More generally, immunosuppressive factorsfwhether agonists or antagonists) may be derived for a number of diseases having a variety of immunoreactive agents without undue experimentation.
  • peptide analog antagonists or agonists may be generated for T cell epitopes on both proteolipid protein or myelin basic protein to treat multiple sclerosis.
  • the naturally occurring polypeptides i.e. MBP or PLP
  • the naturally occurring polypeptides may be associated with a FcR ligand and administered to provide the desired immunosuppressive effect.
  • naturally occurring polypeptides or fragments thereof corresponding to pyruvate dehydrogenase complex or T cell receptor antagonists or agonists derived from T cell epitopes of the same proteins may be used to treat primary biliary cirrhosis.
  • the naturally occurring or derived immunosuppressive factors will be incorporated in a immunomodulating agent as described herein and administered to a patient in need thereof. Effective presentation of the immunosuppressive factor (including agonists resulting from administration of naturally occurring autoantigens) will selectively reduce stimulation of the autoreactive T cells by native peptide thereby relieving the symptoms of the subject immune disorder.
  • the selected immunosuppressive factor and FcR ligand may be effectively administered in any one of a number of forms. More particularly, as described above, the immunomodulating agents of the present invention may combine any form of the respective elements that are functionally effective in selectively suppressing the immune response.
  • the immunomodulating agent may comprise a recombinant (or fusion) polypeptide or protein produced using molecular biology techniques known to those skilled in the art.
  • the FcR ligand may comprise a fragment of a single immunoglobulin region constant domain or, preferably, the entire constant region.
  • the immunomodulating agent may comprise a sterically bound antibody-antigen complex wherein the antigen comprises a T cell receptor antagonist or agonist or naturally occurring autoantigen.
  • the immunomodulating agent may comprise a chimeric antibody wherein an immunosuppressive factor is expressed on the Fab fragment.
  • the immunomodulating agent may comprise two covalently linked molecules which comprise a effective FcR ligand and immunosuppressive factor respectively.
  • chimera or chimeric will be used in their broadest sense to encompass any polynucleotide or polypeptide comprising sequence fragments from more than one source.
  • a genetically engineered polypeptide incorporating a peptide TCR antagonist and a single Fc domain from an IgG molecule could properly be termed a chimeric or fusion protein.
  • a chimeric antibody may comprise a recombinant heavy chains engineered to incorporate a heterologous peptide immunosuppressive factor and a wild type light chains.
  • a chimeric antibody may comprise human light and heavy chains and an engineered human TCR antagonist expressed in a CDR.
  • chimeric immunomodulating agents may comprise FcR ligands and immunosuppressive factors derived from different species such a human and mouse.
  • one aspect of the present invention comprises recombinant polynucleotide molecule encoding a polypeptide wherein said polynucleotide molecule comprises at least one nucleotide sequence corresponding to a Fc receptor ligand and at least one nucleotide sequence corresponding to an immunosuppressive factor.
  • the immunosuppressive factor corresponds to one or more naturally occurring autoantigenic polypeptides or fragments thereof or a T cell receptor antagonist or agonist and the Fc receptor ligand corresponds to at least one constant region domain of an immunoglobulin.
  • the polynucleotide molecule encodes a nucleotide sequence corresponding to an immunoglobulin heavy chain wherein a complementarity determining region has been at least partially deleted and replaced with a nucleotide sequence corresponding to a T cell receptor antagonist or agonist.
  • Compositions comprising mixtures of immunosuppressive factors may also be used effectively in accordance with the teachings herein.
  • DNA constructs comprising the desired immunomodulating agents may be expressed in either prokaryotic or eukaryotic cells using techniques well known in the art. See, for example, Maniatis, et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York, 1982 which is incorporated herein by reference.
  • the engineered plasmid will be transfected into immortal cell lines which secrete the desired product.
  • such engineered organisms can be modified to produce relatively high levels of the selected immunomodulating agent.
  • the engineered molecules may be expressed in prokaryotic cells such as E. coli.
  • products may be separated and subsequently formulated into deliverable compositions using common biochemical procedures such as fractionation, chromatography or other purification methodology and conventional formulation techniques.
  • another aspect of the invention comprises a method for producing an immunomodulating agent for the endocytic presentation of an immunosuppressive factor on the surface of an antigen presenting cell of a vertebrate comprising the steps of: a.
  • transforming or transfecting suitable host cells with a recombinant polynucleotide molecule comprising a nucleotide sequence which encodes a polypeptide comprising at least one Fc receptor ligand and at least one immunosuppressive factor; b. culturing the transformed or transfected host cells under conditions in which said cells express the recombinant polynucleotide molecule to produce said polypeptide wherein the polypeptide comprises at least a part of an immunomodulating agent; and c. recovering said immunomodulating agent.
  • another aspect of the invention comprises transfected or transformed cells comprising a recombinant polynucleotide molecule encoding a polypeptide wherein the polypeptide comprises at least one Fc receptor ligand and at least one immunosuppressive factor.
  • the immunosuppressive factor preferably corresponds to one or more naturally occurring autoantigenic polypeptides or fragments thereof or a T cell receptor antagonist or agonist and the Fc receptor ligand preferably comprises at least part of an immunoglobulin constant region domain. More preferably, the immunomodulating agent comprises a poly peptide or chimeric antibody wherein at least one complementarity determining region (CDR) has been replaced with a T cell receptor antagonist or agonist.
  • CDR complementarity determining region
  • compositions of the present invention may comprise one or more of the immunomodulating agents described herein, in combination with one or more pharmaceutically of physiologically acceptable carriers, diluents or excipients.
  • Such composition may comprise buffers such as neutral buffered saline, phosphate buffered saline and the like, carbohydrates such as glucose, mannose, sucrose or dextrans, mannitol, proteins, polypeptides or amino acids such as glycine, antioxidants, chelating agents such as EDTA or glutathione, adjuvants (e.g. aluminum hydroxide) and preservatives.
  • preferred embodiments comprise pharmaceutically acceptable carriers that do not include adjuvants capable of inducing costimulatory molecules.
  • the pharmaceutical compositions of the present invention may contain one or more additional active ingredients, such as, for example, cytokines like B-interferon.
  • a further aspect of the present invention comprise pharmaceutical compositions for the endocytic presentation of an immunosuppressive factor on the surface of an antigen presenting cell of a vertebrate comprising at least one immunomodulating agent and a pharmaceutically acceptable carrier, said at least one immunomodulating agent comprising at least one Fc receptor ligand and at least one immunosuppressive factor.
  • the invention comprises methods for the preparation of a pharmaceutical composition to treat an immune disorder comprising combining at least one immunomodulating agent with a physiologically acceptable carrier or diluent wherein said immunomodulating agent comprises at least one Fc receptor ligand and at least one immunosuppressive factor.
  • the immunosuppressive factor may comprise one or more naturally occurring autoantigenic polypeptides or fragments thereof or a T cell receptor antagonist or agonist and the Fc receptor ligand may comprise at least part of a immunoglobulin constant region domain.
  • the immunomodulating agent will be in the form of a recombinant polypeptide or a chimeric antibody.
  • immunomodulating agents comprising chimeric antibodies are a particularly preferred aspect of the invention. Such antibodies may be formed by substituting a immunosuppressive factor, typically a peptide TCR antagonist or agonist, for at least part of one or more of the complementarity determining regions (CDR).
  • the nucleotide sequence coding for the heavy chain may be engineered to replace all or part of at least one CDR with a peptide or peptide analog of all or part of an autoantigen.
  • the recombinant heavy chains can complex with wild type light chains to form an immunoreactive tetramer displaying two immunosuppressive factors.
  • the immunoglobulin molecules may be selected from the species to be treated so as to minimize the generation of a harmful immune response (i.e. a human anti-mouse response). As the constant region of the selected immunoglobulin is essentially unmodified, this form of immunomodulating agent is readily endocytosed allowing for effective presentation of the associated immunosuppressive factor.
  • the immunomodulating agents of the present invention may comprise an antigen-antibody complex wherein the antigen is an immunosuppressive factor.
  • the antigen is an immunosuppressive factor.
  • modern immunological techniques may be used to generate and purify the desired antibodies which are preferably monoclonal.
  • a selected peptide antagonist i.e. an analog of a peptide autoantigen
  • agonist may be injected into a mouse to provide immunoreactive cells which may then be harvested and immortalized using standard methods.
  • the murine monoclonal may be "humanized” using conventional recombinant procedures leaving a small murine variable region expressed on an otherwise human immunoglobulin that will not provoke a harmful immune response in a patient.
  • the monoclonal antibody is complexed with the immunosuppressive factor to form the desired immunomodulating agent which may then be formulated and administered as described above.
  • the immunosuppressive factor to form the desired immunomodulating agent which may then be formulated and administered as described above.
  • phagocytation should be relatively rapid and presentation of the attached immunosuppressive factor efficient.
  • embodiments may comprise the Fc receptor ligands corresponding to the entire constant region, it must be emphasized that the present invention does not require that the administered immunomodulating agent comprise an intact immunoglobulin constant region. Rather, any FcR ligand that can bind to the FcR and undergo endocytosis may be used in conjunction with the selected immunosuppressive factor. Specifically, single domains of constant regions or fragments thereof may be combined with peptide antagonists to form monomeric polypeptides (having a single amino acid chain) that can suppress the immune system in accordance with the teachings herein.
  • Such fusion proteins may be constructed which, having the minimum effective FcR ligand and/or immunosuppressive factor, may be much more stable thereby facilitating delivery and possibly increasing bioavailabilit ⁇ .
  • these engineered polypeptides or proteins may be able to be administered over a period of time without provoking an immune response as is seen when administering whole antibodies of heterologous species.
  • relatively small chimeric polypeptides may prove to be effective immunomodulating agents.
  • non-peptide based molecular entities may prove to be efficient FcR ligands, immunosuppressive factors or, in combination, immunomodulating agents.
  • molecular entities peptide based or non-peptide based
  • FcR ligand that function effectively in a selected role
  • FcR ligand may be provided using current procedures such as combinatorial chemistry, directed evolution or rational drug design.
  • rational drug design it may be possible to use rational drug design to fashion a small non-peptide molecular entity that effectively binds to a previously elucidated Fc receptor.
  • the derived FcR ligand may then be covalently linked (or otherwise reversibly associated) with an immunosuppressive factor such as a peptide antagonist to provide an immunomodulating agent that exhibits particular stability or other desirable traits.
  • the immunomodulating agents or fusion proteins of the present invention may be immobilized or aggregated to provide constructs or structures that advantageously induce the production of anti- inflammatory cytokines such as IL-10 and IL-6.
  • the absolute form of the aggregated or immobilized constructs is not critical and in the context of the present invention encompasses any configuration of the disclosed immunomodulating agents.
  • the aggregated or immobilized constructs may be soluble or insoluble and may consist exclusively of the agent or may comprise a carrier, matrix, structure or paniculate associated with the agent.
  • the disclosed agents may be associated or complexed with microparticle carriers comprising any biologically compatible material or may be embedded in a relatively long lasting polymer matrix.
  • exemplary microparticluate carriers may comprise proteins, saccharides, lipids or synthetic and natural polymers.
  • the complexed agents will be aggregated using techniques well known in the art.
  • the aggregates may be formed using heat, chemical crosslinking or precipitation.
  • the resulting aggregates may be soluble, insoluble or some mixture thereof.
  • denaturation of immunoglobulins exposes hydrophobic groups that favor intermolecular rather than intramolecular interactions. These intermolecular interactions promote aggregation. For example, heating immunoglobulins (i.e. immunomodulating agents) for 15 minutes at 63°C leads to formation of soluble aggregates that possess many biological properties similar to immune complexes.
  • Such aggregates or constructs are particularly effective for providing the desired immune response in a patient in need thereof.
  • the aggregation or immobilization of the immunomodulating agents allows them to imitate opsonized antigens.
  • target cells efficiently digest opsonized particles and secrete biological response modifiers to enhance or down-regulate the inflammatory response as appropriate.
  • the constructs act to mimic a late stage immune response where the inflammatory reaction to the initial infection is being pondered. That is, the aggregated or immobilized immunomodulating agents "fool" the immunoactive cells into thinking that the infective agent has been eliminated and that the protective immune response is no longer needed.
  • the activated APCs secrete biological response modifiers such as IL-10 and IL-6 that down-regulate active T cells.
  • biological response modifiers such as IL-10 and IL-6 that down-regulate active T cells.
  • the secretion of such biological response modifiers will act to down-regulate autoreactive T cells that are responsible for the subject autoimmune disorder.
  • compositions of the present invention provide for the induction of biological response modifiers including cytokines involved in the pathways of Th, / Th 2 development and known to be produced by cells able to function as APCs.
  • the cytokines that seem to be involved in development include IL-4, IL-12, and IL-10.
  • IL-6 that is produced by monocytes and appears to induce IL-4 synthesis, is involved in the development of Th 2 T cells.
  • IL-10 can be produced by monocytes and function to inhibit APC dependent T cell activation by apparently down-regulating MHC class II expression and inhibiting the up-regulation of costimulatory molecules.
  • the present invention allows for the selective stimulation of these and other beneficial biological response modifiers.
  • aggregated immunomodulating agents may be used to ameliorate symptoms in EAE mice (Ex. XXV) and induce the production of selected biological response modifiers in activated cells (Ex. XXVI).
  • Fig. 22 shows that the administration of aggregated constructs dramatically reduces the clinical indications of disease in EAE mice.
  • macrophages, dendritic cells and B cells were purified, incubated with aggregated Ig-PLPl and tested for production of IL-6 and IL-10.
  • the results, shown in Figs. 23A and 23B indicate that macrophages produce both IL-6 and IL-10 while dendritic cells produce only IL-10. It appears that B cells do not produce either cytokines when stimulated with aggregated immunomodulating agents.
  • IL-10 is an anti-proliferative cytokine and is known to inhibit the production of other cytokines.
  • APCs that bind Ig-PLPl (particularly aggregated Ig-PLPl ) and subsequently produce IL- 10 could affect T cell-APC interactions in at least two ways.
  • IL-10 is known to both inhibit the expression of class II molecules and the up-regulation of costimulatory molecules.
  • IL-10 may inhibit the synthesis of cytokines that are required for the activation of the T cells.
  • treated APCs could produce IL-6, a cytokine known to favor the development of Th 2 type cells.
  • IL-6 produced by the APCs upon binding of the immunomodulating agents may favorably affect T cell-APC interactions and induce modulation of the T cells. Further, if TGF ⁇ is produced by the APCs this also could have a modulatory effect on T cells.
  • aggregated or immobilized immunomodulating agents may be particularly effective for the induction of anti-inflammatory cytokine production.
  • treatment with immobilized or aggregated immunomodulating agents may induce: production of soluble mediators by APCs, that can directly or indirectly down-regulate the activity of pathogenic T cells; may suppress the function of APCs by down-regulating the expression of MHC class II molecules and co-stimulatory molecules; may lead to presentation of therapeutic epitopes by non-professional APCs or enhance their presentation by professional APCs leading to antigen activated cell death or anergy.
  • these effects may translate into: prevention of generation of pathogenic T cells; functional switch of T cells from pathogenic to non-pathogenic state; generation of disease suppressing T cells; and elimination of pathogenic T cells. This can lead to prevention, stabilization or remission of autoimmune disorders in accordance with the teachings herein.
  • compositions of the present invention may be formulated to provide desired stability and facilitate the selected form of administration.
  • the compositions may be administered using all the conventional routes including, but not limited to, oral, vaginal, aural, nasal, pulmonary, intravenous, intracranial, intraperitoneal, subcutaneous, or intramuscular administration.
  • the compositions described herein may be administered as part of a sustained release implant.
  • compositions of the present invention may be formulated as a lyophilizate or spray dried formulation, utilizing appropriate excipients which provide enhanced stability. These preferred formulations may then be administered using dry powder inhalers or, when combined with a carrier or propeliant, from a metered dose inhaler, nebulizer, atomizer, spray bottle or dropper.
  • the present invention is useful for the treatment of any vertebrate comprising an immune system subject to down-regulation.
  • the invention is particularly useful in those vertebrates such as mammals that possess cellular immune responses.
  • the vertebrate to be treated will be in a neonatal or infant state.
  • a further aspect of the invention comprises a method for treating an immune disorder comprising administering to a patient a therapeutically effective amount of a pharmaceutical composition comprising an immunomodulating agent in combination with a physiologically acceptable carrier or diluent wherein said immunomodulating agent comprises at least one Fc receptor ligand and at least one immunosuppressive factor.
  • the immunosuppressive factor may comprise a T cell receptor antagonist or agonist and the Fc receptor ligand may comprise at least part of a immunoglobulin constant region domain.
  • the immunomodulating agent will preferably be in the form of a recombinant polypeptide or a chimeric antibody.
  • the methods may be used treat immune disorders comprising autoimmune disorders, allergic responses and transplant rejection and are particularly useful in treating autoimmune disorders selected from the group consisting of multiple sclerosis, lupis, rheumatoid arthritis, scleroderma, insulin-dependent diabetes and ulcerative colitis.
  • autoimmune disorders selected from the group consisting of multiple sclerosis, lupis, rheumatoid arthritis, scleroderma, insulin-dependent diabetes and ulcerative colitis.
  • the compositions, compounds and methods of the present invention are particularly useful for inducing tolerance in neonatal or infant mammals thereby preventing or reducing future autoimmunity.
  • infant refers to a human or non-human mammal during the period of life following birth wherein the immune system has not yet fully matured.
  • infant mammals which have essentially just been born.
  • newborn and nonate refer to a subset of infant mammals which have essentially just been born.
  • Other characteristics associated with “infants” according to the present invention include an immune response which has (i) susceptibility to high zone tolerance (deletion/anergy of T cell precursors, increased tendency for apoptosis); (ii) a Th 2 biased helper response (phenotypical particularities of neonatal T cells; decreased CD40L expression on neonatal T cells); (iii) reduced magnitude of the cellular response (reduced number of functional T cells; reduced antigen-presenting cell function); and (iv) reduced magnitude and restricted type of humoral response (predominance of lgM hl9 ⁇ lgD'° w , B cells, reduced cooperation between Th and B cells).
  • the disclosed immunomodulating agents may be administered to an infant mammal wherein maternal antibodies remain present in detectable amounts.
  • the pregnant mother may be inoculated with the disclosed compositions so as to produce the desired T cell tolerance in the fetus.
  • the induced T cell tolerance may confer resistance to the later development of an autoimmune disease associated with the administered immunomodulating agent.
  • the pharmaceutical compositions of the present invention may be administered in a manner appropriate to the disease to be treated (or prevented).
  • the quantity and frequency of administration will be determined by such factors as the condition of the patient, and the type and severity of the patients disease.
  • the pharmaceutical compositions described herein may be administered at a dosage ranging from 1 mg to 50 mg/kg, although appropriate dosages may be determined by clinical trials. Those skilled in the art will appreciate that patients may be monitored for therapeutic effectiveness by MRI or signs of clinical exacerbation.
  • the immunomodulating agent binds to one or more Fc receptors present on the surface of at least one type of antigen presenting cell.
  • FcR ligand will, at least to some extent, determine which class of Fc receptor is used to internalize the immunomodulating agent. That is, a FcR ligand corresponding to an IgG constant region will be bound by a different class of Fc receptor than a FcR ligand corresponding to an IgE constant region.
  • different classes of Fc receptors are expressed on different types of antigen presenting cells it is possible to present the immunosuppressive factor on selected APCs.
  • an FcR ligand corresponding to an IgG constant region is likely to be endocytosed by a macrophage or neutrophil and presented accordingly. This is of interest in that certain APCs are more efficient at presenting various types of antigens which, in turn, may influence which T cells are activated.
  • the entire immunomodulating agent is subjected to receptor mediated endocytosis by the APC and usually becomes localized in clathrin-coated vesicles.
  • the immunomodulating agent is processed for eventual presentation at the surface of the APC. Processing generally entails vesicle transport of the immunomodulating agent to the lysosome, an organelle comprising an acidic pH and selected enzymes including proteases.
  • the immunomodulating agent is digested to provide a free immunosuppressive factor which, for the purposes of the instant invention, may be in the form of a protein, polypeptide or peptide.
  • the released immunosuppressive factor comprises an autoantigenic polypeptide or protein, or fragment thereof
  • the factor will be further digested to provide one or more T cell receptor agonists.
  • the peptide is an antagonist or an agonist (either administered directly as part of the immunomodulating agent or derived from an administered autoantigenic polypeptide)
  • average presented peptide lengths may be, for example, on the order of 5 to 30 amino acids.
  • TCR antagonist as the immunosuppressive factor presented in concert with the class II MHC molecules. Accordingly, such antagonists (which may be peptide analogs) will be used for the purposes of the following discussion. However, it must be emphasized that the present invention may be used for the receptor mediated endocytic presentation of any immunosuppressive factor that down- regulates an immune response. As such, T cell receptor agonists which provide the desired reduction in immunogenic response may be used as immunosuppressive factors and are in the purview of the present invention. Moreover, as previously indicated the presented agonist or agonists may be administered directly as the immunosuppressive factor or may be derived from an immunosuppressive agent comprising one or more autoantigenic polypeptides or fragments thereof.
  • the administered immunosuppressive factor may be an agonist peptide that will be presented in concert with MHC complexes without substantial processing following endocytic separation from the FcR ligand.
  • the immunosuppressive factor will preferably comprise at least one autoantigenic polypeptide or fragments thereof.
  • the immunosuppressive factor will typically be processed (digested) following cleavage from the FcR ligand to provide one or more peptide agonists that will then be presented in concert with the MHC class II molecules in accordance with the teachings herein. In either case, efficient presentation of the appropriate agonist to the T cell receptor may be used to down-regulate the immune response.
  • a T cell may have previously been sensitized to a peptide agonist corresponding to a fragment of myelin basic protein.
  • this autoagonist is continuously presented thereby activating an immune response directed to constituents of the myelin sheath.
  • the sensitized individual T cells express thousands of receptors which selectively bind to the presented autoagonist and signal the cell.
  • the sensitized T ceil acts to mount a response i.e. secrete interleukin.
  • a TCR antagonist is presented in concert with MHC class II molecules the T cell will recognize the presented complex but will not be activated.
  • the presented TCR antagonist binds effectively to the TCR of a sensitized T cell thereby precluding binding of a presented autoantigen or fragment thereof.
  • the immunosuppressive factor-TCR complex does not signal the T cell to mount a response.
  • the binding of the immunosuppressive factor non-reactive agonist or antagonist
  • a harmful immune response to the continuously presented autoantigen comprising a natural agonist is averted.
  • efficient FcR mediated presentation of agonists may be used to down-regulate the immune response of a mammal in accordance with the teachings herein.
  • the ultimately presented agonist(s) may be administered directly as the immunosuppressive factor or may be derived from autoantigenic polypeptide immunosuppressive factors which are endocytically proteolyzed. While not wishing to be bound to any particular theory, it is believed that the autoantigenic agonists may be presented by nonprofessional and/or non-activated APCs lacking costimulatory molecules. As discussed above it was suprisingly found that this type of presentation ultimately induces the inactivation of T cells.
  • the immunomodulating agent constructs are administered in vehicles which do not contain an adjuvant so as to minimize or eliminate the activation and/or production of costimulatory molecules.
  • Particularly preferred embodiments of this aspect of the present invention may encompass immunosuppressive factors comprising one or more autoantigenic polypeptides or fragments thereof.
  • constructs in accordance with this embodiment may comprise a fusion or chimeric IgG wherein at least one of the CDR regions has been at least partially replaced with a peptide agonist derived from PLP.
  • constructs when administered in therapeutically effective amounts in an adjuvant free pharmaceutically effective carrier should be able to alleviate at least some symptoms associated with multiple sclerosis.
  • fusion polypeptides comprising the Fc region of an IgG covalently linked to a immunosuppressive factor comprising the autoantigenic proteins MBP and PLP. These constructs would again be administered in adjuvant free carriers.
  • the administered autoantigenic polypeptide(s) will likely be endocytically proteolyzed to provide several different peptide agonists which will then be presented concomita ⁇ tly.
  • Such presentation of multiple agonists provides a solution to any difficulties associated with epitope spreading and population diversity.
  • autoimmune disorders may be the result of more than one autoantigenic epitope on one or more polypeptides.
  • different individuals in a subject population may develop autoimmunity to different epitopes on one or more autoantigenic polypeptides.
  • the present invention can very cleverly obviate such difficulties by administering one or more autoantigenic polypeptides, or fragments thereof which, following normal endocytic processing, will result in the presentation of more than one agonist peptide on the surface of the APCs. That is, a full spectrum of peptide agonists may be efficiently presented using the compositions and techniques disclosed herein. It should be emphasized that the presentation of such agonists would not likely be accomplished without efficient FcR mediated uptake as is provided by the present invention. More particularly, it is unlikely that one could achieve therapeutically effective levels of agonist presentation through the simple administration of naturally occurring autoantigenic polypeptides (i.e.
  • the present invention provides for effective presentation of the desired agonists at relatively low dosing.
  • MBP myelin basic protein
  • PLP proteolipid protein, has been implicated in the etiology of multiple sclerosis; PLP1: a peptide fragment of PLP comprising aa residues 139-151; PLP-LR: a peptide analog of PLP1, does not activate PLP1 pulsed cells; PLP2: a peptide fragment of PLP comprising aa residues 178-191; Ig-W: an Ig construct (used herein as a control) comprising the heavy chain variable region of the anti-arsonate antibody
  • Ig-PLPl the same construct as Ig-W except that the heavy chain CDR3 was replaced with aa residues 139-151 of PLP
  • Ig-PLP-LR the same construct as Ig-W except that the heavy chain CDR3 was replaced with a peptide analog of aa residues 139-151 of PLP
  • Ig-HA (used as a control herein) the same construct as Ig-W except that the heavy chain CDR3 was replaced with aa residues 110-120 of influenza virus HA
  • PPD purified protein derivative, whole Mycobacterium tubercuolosis extract used as a control activator.
  • mice for purposes of explanation only and not for purposes of limitation, the present invention will be primarily demonstrated in the exemplary context of mice as the mammalian host. Those skilled in the art will appreciate that the present invention may be practiced with other mammalian hosts including humans and domesticated animals.
  • EAE experimental encephalomyelitis
  • PLP myelin autoantigens
  • MBP myelin basic protein
  • amino acids are referred to by their standard three-letter or one-letter code. Unless otherwise specified, the L-form of the amino acid is intended. When the 1 -letter code is used, a capital letter denotes the L-form and a small letter denotes the D-form.
  • the one letter code is as follows: A, alanine; C, cysteine; D, aspartic acid; E, glutamic acid; F, phenylalanine; G, glycine; H, histidine; I, isoleucine; K, lysine; L, leucine; M, methionine; N, asparagine; P, proline; 0, glutamine; R, arginine; S, serine; T, threonine; V, valine; W, tryptophan; and Y, tyrosine. All peptides used in the following examples were produced by Research Genetic, Inc. (Huntsville, Alabama) using solid state methodology and purified on HPLC columns to > 90% purity using conventional methods.
  • PLP1 peptide (HSLGKWLGHPNKF: SEQ. ID No. 1) encompasses an encephalitogenic sequence corresponding to aa residues 139-151 of naturally occurring proteolipid protein.
  • PLP-LR (HSLGKLLGRPNKF:SEQ. ID No. 2) is an analog of PLP1 in which Trp144 and His147 were replaced with Leu and Arg (underlined), respectively.
  • PLP1 and PLP-LR bind well to l-A s class II molecules (i.e. an MHC class II structure produced by a specific strain of mice).
  • PLP2 peptide NKTTCQSIAFPSK:SEQ. ID No.
  • HA peptide (sequence not shown) corresponds to aa residues 110- 120 of the hemagglutinin of the Influenza virus. HA binds to 1-E° class II molecules and is used here as control peptide.
  • Two immunoglobulin-peptide chimeras designated Ig-PLPl and Ig-PLP-LR and shown schematically in Figure 1, were constructed to express peptides PLP1 and PLP-LR as described in Example 1. In both cases, the heavy chain CDR 3 loop was deleted and replaced with nucleotide sequences coding for the selected peptide. Conventional DNA sequencing analysis indicated insertion of peptide nucleotide sequences in the correct reading frame.
  • genes used to construct these chimeras include the gene coding for the BALBK lgG 2 b constant region as described by Gillian et al., Cell. 33:717,1983, the gene coding for the 91 A3 heavy chain variable region as described by Ruthban et al., J. Mol. Bio., 202:383-398, 1988, and the gene coding for the entire 91 A3 kappa light chain as described by Gary et al., Proc. Natl. Acad. Sci., 84:1085-1089, 1987, all of which are incorporated herein by reference.
  • the 91A3V handling gene was subcloned into the EcoRI site of pUC19 plasmid and used as template DNA in PCR mutagenesis reactions to generate 91A3V H fragments carrying PLP1 (91A3V H -PLP1) and PLP-LR (91A3V H -PLP-LR) sequences in place of CDR3. Nucleotide sequencing analysis indicated that full PLP1 and PLP-LR sequences were inserted in the correct reading frame (not shown).
  • the 91A3V H -PLP1 and 91A3V H -PLP-LR fragments were then subcloned into the EcoRI site of pSV2-gpt-Cg2b in front of the exons coding for the constant region of a Balb/cg2b which generated pSV2- gpt-91 A3V H -PLP1 -Cg2b and pSV2-gpt-91A3V H -PLP1 -LR-Cg2b plasmids, respectively.
  • plasmids were then separately cotransfected into the non-lg producing SP2/0 B myeloma cells with an expression vector carrying the parental 91A3 light chain, pSV2-neo-91A3L.
  • Transfectants producing Ig chimeras were selected in the presence of geneticin and mycophenolic acid. Transfectants were cloned by limiting dilution and final clones secreted 1 to 4 mg/mL of Ig-PLPl or Ig- PLP-LR (collectively, the Ig-PLP chimeras).
  • the selected cell lines designated lg-PLP1-9B11 and lg-PLP-LR-21A10, are maintained in permanent storage in the inventor's laboratory.
  • Ig-HA an IgG molecule carrying in place of the D segment the HA110-120 T helper epitope from the HA of influenza virus that differs from Ig-PLPl and Ig-
  • Ig-W is the product of unmodified (wild-type) 91A3V H gene, Balb/cg2b constant region and 91 A3 kappa light chain. Therefore it differs from Ig-PLPl and Ig-PLP-LR in the CDR3 region which comprises the parental D segment.
  • lg-PLP2 is a chimeric antibody that carries within the heavy chain CDR3 loop aa residues 178-191 of PLP.
  • Conventional cloning, sequencing, and purification procedures were used to generate the appropriate cell lines and are similar to those described by Zaghouani et al. (previously cited) and those previously used to generate Ig-HA, Zaghouani et al., Science. 259:224-227, 1993 also incorporated herein by reference.
  • Ig-PLP chimeras were purified from culture supernatant on columns made of rat-anti-mouse kappa chain mAb and coupled to CNBr activated Sepharose 4B (Pharmacia).
  • Rat-anti-mouse kappa chain mAb RAM 187.1 or ATCC denotation, HB-58
  • mouse anti-rat kappa light chain mAb MAR 18.5 or ATCC denotation, TIB 216 were obtained from the ATCC.
  • These hybridomas were grown to large scale and purified from culture supernatant on each other.
  • the rat anti-mouse kappa mAb was used to prepare the columns on which the Ig-PLP chimeras were purified from culture supernatant. To avoid cross contamination separate columns were used to purify the individual chimeras.
  • Example III Purification of Proteolipid Protein Native proteolipid protein or PLP was purified from rat brain according to the previously described procedure of Lees et al., in Preparation of Proteolipids, Research Methods in Neurochemistry, N. Marks and R. Rodnight, editors. Plunemum Press, New York, 1978 which is incorporated herein by reference.
  • brain tissue was homogenized in 2/1 v/v chloroform/methanol, and the soluble crude lipid extract was separated by filtration through a scintered glass funnel.
  • PLP was then precipitated with acetone and the pellet was redissolved in a mixture of chloroform/methanol/acetic acid and passed through an LH-20-100 sephadex column (Sigma) to remove residual lipids.
  • LH-20-100 sephadex column Sigma
  • PLP1 and PLP-LR peptides prepared in Example I were coupled to KLH and BSA as described in Zaghouani et al.,
  • New Zealand white rabbits were purchased from Myrtle's Rabbitr ⁇ (Thompson Station, TN). The rabbits were immunized with 1 mg peptide-KLH conjugates in complete Freund's adjuvant (CFA) and challenged monthly with 1 mg conjugate in incomplete Freund's adjuvant (IFA) until a high antibody titer was reached.
  • CFA complete Freund's adjuvant
  • IFA incomplete Freund's adjuvant
  • the peptide-BSA conjugates were coupled to sepharose and used to purify anti-peptide antibodies from the rabbit anti-serum.
  • RIA radioimmnoassays
  • Microtiter 96-well plates were coated with the rabbit anti-peptide antibodies made in Example IV (5 mg/mL) overnight at 4°C and blocked with 2% BSA in PBS for 1 hour at room temperature. The plates were then washed 3 times with PBS, and graded amounts of Ig-PLPl and Ig-PLP-LR were added and incubated for 2 hours at room temperature. After 3 washes with PBS, the captured Ig-PLPl and Ig-PLP-LR were detected by incubating the plates with 100 x 10 3 cpm 125 l-labeled rat anti-mouse kappa mAb for 2 hours at 37°C. The plates were then washed 5 times with PBS and counted using an LKB gamma counter. Shown are the mean ⁇ SD of triplicates obtained with 27 mg/mL of chimeras.
  • the rabbit antibodies directed to synthetic PLP1 and PLP-LR peptides recognized the chimeric antibodies Ig-PLPl and Ig-PLP-LR produced in Example II. More specifically, when Ig-PLPl and Ig-PLP-LR were incubated on plates coated with rabbit anti-PLPI they were captured in significant quantity and bound labeled rat anti- mouse kappa chain mAb (Fig. 2A). Similarly, both Ig-PLPl and Ig-PLP-LR were captured by rabbit anti-PLP-LR (Fig. 2B). Conversely, Ig-W, the wild type 91 A3 murine antibody without an exogenous peptide and an IgM control antibodies (not shown), did not show significant binding to the rabbit antibodies.
  • PLP1 -specific T cell hybridomas 5B6 and 4E3 and the IL-2 dependent HT-2 T helper cells were obtained from The Eunice Kennedy Shriver Center, Waltham, MA.
  • the 5B6 and 4E3 T cells recognize the peptide PLP1 in association with l-A s class II MHC and produces IL-2 when incubated with it as reported by Kuchroo et al., J. Immunol. 153:3326- 3336, 1994 which is incorporated herein by reference.
  • Kuchroo et al. report that when stimulated with PLP1 and then with PLP-LR both 5B6 and 4E3 cells no longer produce IL-2.
  • PLP1 in the presence of PLP-LR apparently inhibits IL-2 production.
  • T cell hybridomas for various agonists was performed as follows. Irradiated (3,000 rads) splenoc ⁇ tes from SJL mice were used as antigen presenting cells (APCs) for this Example. The irradiated splenoc ⁇ tes were incubated in 96-well round bottom plates (5 x 10 s cells/well/50 ml) with graded concentrations of antigens (100 ml/well). After one hour, T cell hybridomas, i.e. 5B6 or 4E3 (5 X 10" cells/well/50 ml) were added and the culture was continued overnight.
  • Irradiated (3,000 rads) splenoc ⁇ tes from SJL mice were used as antigen presenting cells (APCs) for this Example. The irradiated splenoc ⁇ tes were incubated in 96-well round bottom plates (5 x 10 s cells/well/50 ml) with graded concentrations of antigens (100 ml/well). After one hour,
  • Activation (or proliferation) of the T cells was assessed by measuring production of IL-2 in the culture supernatant. This was done by 3 H-thymidine incorporation using the IL-2 dependent HT-2 cells. That is, when IL-2 is present (i.e. secreted by activated T cells) the HT-2 cells proliferate, incorporating labeled thymidine from the surrounding media.
  • the culture media used to carry out these assays was DMEM supplemented with 10% FBS, 0.05 mM 2- mercaptoethenol, 2 mM glutamine, 1 mM sodium puryvate and 50 mg/mL gentamycin sulfate.
  • culture supematants 100 ml/well were incubated with HT-2 cells (1x 10" cells/well/100 ml) in 96-well flat bottom plates for 24 hours. Subsequently 1 mCi 3 H-th ⁇ midine was added per well and the culture was continued for an additional 12-14 hours. The cells were then harvested on glass fiber filters and the non incorporated 3 H-thymidine was washed away. Incorporated thymidine was then counted using the trace 96 program and an Inotech b counter. It will be appreciated that those wells containing higher levels of IL-2 (secreted by the activated T cell hybridoma lines) will induce higher levels of HT-2 cell proliferation and register increased levels of 3 H-thymidine incorporation.
  • T cell hybridomas 4E3 (Fig. 3A) and 5B6 (Fig. 3B) produced substantial levels of IL-2 following stimulation by APCs previously incubated with Ig-PLP 1, PLP1 and native PLP.
  • the negative controls Ig-W, Ig-HA, and PLP2 peptide did not induce the production of IL-2 by the T cells.
  • both Ig-PLP-LR and PLP-LR peptide did not stimulate 5B6 and 4E3 to produce significant levels of IL-2.
  • the concentration of antigen was 0.1 mM for lg-PLP1, Ig-PLP-LR, Ig-HA, and Ig-W; 1 mM for PLP1 , and PLP2 peptides; and 1.1 mM for PLP. Each value represents the mean ⁇ SD of triplicate wells.
  • TCR TCR.
  • the PLP1 peptide was released from the Ig by endocytic processing and bound MHC class II l-A s molecules. Accordingly, the regions flanking the PLP1 peptide do not appear to interfere with the endocytic processing of Ig-PLPl or the binding of the PLP1 peptide to the MHC class II structure.
  • one aspect of the present invention is to provide an in vitro model for the continuous endocytic presentation of agonist ligands.
  • the present invention provides methods for the effective in vitro endocytic presentation of a T cell antagonist comprising the steps of: a. providing a medium comprising a plurality of antigen presenting cells expressing Fc receptors; and b. combining said medium with a immunomodulating agent containing composition wherein the composition comprises an immunomodulating agent having at least one Fc receptor ligand and at least one immunosuppressive factor and a compatible carrier.
  • the immunosuppressive factor will be at least one T cell receptor antagonist and the Fc receptor ligand will be at least part of a immunoglobulin constant region domain.
  • the immunomodulating agent will comprise a recombinant polypeptide or a chimeric antibody.
  • Ig-PLPl or any immunoglobulin associated agonist
  • the disclosed system may be used to investigate antagonism in a situation similar to the in vivo presentation of autoantigens.
  • T cell activation assays were performed with free PLP1 peptide, native PLP, and Ig-PLPl. The results of the assays are shown in Fig.4.
  • IL-2 production was measured by 3 H- thymidine incorporation using the IL-2 dependent HT-2 cells as described in Example VI. Each point represents the mean of triplicates. The standard deviation did not exceed 10% of the mean value.
  • Fig. 4 shows that, although the maximum activation levels varied among the three different agonists, the levels required to stimulate the T cells were much lower for Ig-PLPl than for either free PLP1 or native PLP. That is, it took substantially less lg-PLP1 to stimulate the cell line than either the native PLP or the free peptide (on the order of 1/100). Specifically, stimulation to half the maximum level required less Ig-PLPl (0.005 mM) than PLP (0.5 mM) or PLP1 peptide
  • Fig. 4 unambiguously shows that Ig-PLPl is more efficient in presenting PLP1 peptide in combination with MHC class II molecules than either the free peptide or the native protein.
  • SJL splenocytes (used as APCs) were incubated in 96-well round bottom plates (5 x 10 5 cells/well/50 ml) with the selected agonist (1 mM PLP1 peptide, 0.05 mM Ig-PLPl or 7 mM PLP) and various concentrations of antagonist (100 ml/well) for 1 hour. Subsequently, 4E3 T cell hybridomas (5 X 10 4 cells/well/50 ml) were added and the culture was continued overnight. IL-2 production in the supernatant, determined as in Example VI using HT-2 cells, was used as measure of T cell activation. The results of this assay are shown in Figure 5.
  • Figures 5A, 5B and 5C show antagonism of free PLP1 peptide (5A), Ig-PLPl chimeric immunoglobulin (5B) and native PLP (5C) respectively.
  • the antagonists were Ig-PLP-LR (squares) and PLP-LR (circles) with controls of Ig-W (diamonds) and PLP2 (triangles).
  • Cpm values obtained when the APCs were incubated with the agonist but no antagonist was used as control thymidine incorporation This value was 7,503 ⁇ 1,302 for Ig-PLPl; 31,089 ⁇ 3,860 for PLP1 peptide; and 8,268 ⁇ 915 for PLP.
  • the cpm value obtained when the APCs were incubated with no agonist or antagonist was used as background (BG). This value was 1,560 ⁇ 323 for ig-PLPI; 2,574 ⁇ 290 for PLP1 peptide; and 2,127 ⁇ 177 for PLP.
  • the percent control thymidine incorporation was calculated as follows: [(cpm obtained in the presence of test antagonist) - (BG)] / [(cpm control thymidine incorporation value) - (BG)]. Each point represents the mean of triplicates.
  • FIG. 5A shows that when T cells were incubated with APCs in the presence of both PLP1 and Ig-PLP-LR, a substantial decrease in IL-2 production occurred as the concentration of Ig-PLP-LR increased. A similar decline in IL-2 production was evident when the synthetic PLP-LR peptide was used during T cell activation with PLP1 peptide.
  • Figs. 5B and 5C show that Ig-PLP-LR inhibited T cell activation mediated by Ig-PLPl while free PLP-LR, like the negative control PLP2 peptide, did not show any significant antagonism.
  • Fig. 5B also shows that Ig-W, the wild type 91 A3 immunoglobulin without any exogenous peptide exhibits partial inhibitory activity in Ig-PLPl mediated T cell activation. It is believed that this may be the result of competition for binding to the FcR on the
  • Ig-PLPl Ig-W share identical lgG2b constant regions.
  • a maximum of 50% inhibition in IL-2 production was seen when the activation of T cells by Ig-PLPl was carried out in the presence of Ig-W.
  • Ig-W would compete with Ig-PLPl for FcR binding and internalization thereby diminishing the activation of T cells. That is, as the concentration of Ig-W increases, less Ig-PLP 1 will bind to FcR and be internalize by the APCs resulting in a diminished presentation and corresponding IL-2 production. It is important to note that this Ig-W mediated reduction in response is not the result of antagonistic effects but rather simply a result of competition for FcR binding.
  • the presented Ig-W epitopes are not TCR antagonists for PLP1 and do not interact with the PLP1 specific TCRs.
  • Fig. 5C shows that Ig-PLP-LR, but not Ig-W, significantly reduces the activation of T cells by native PLP.
  • Ig-W is likely internalized in a different manner than native PLP, (Fc receptor versus simple fluid phase pinocytosis) there should not be any direct competition for uptake and processing and hence no inhibition.
  • PLP2 was prepared as in Example II using the sequence detailed in Example I.
  • the % control thymidine incorporation was calculated as in Example VIII. Results of the assay are shown in Fig. 6 wherein each column represents the mean ⁇ SD of triplicates.
  • the present Example supports the position that both efficient presentation on the MHC class II structure and an effective peptide analog provide the most significant results. That is, even though the lg-PLP2 chimeric antibody is taken up and processed, efficient presentation of the PLP2 peptide by l-A s will not preclude activation of the T-cells as it is not an analog of the native PLP agonist. Accordingly, simple competition binding to MHC class II molecules on the antigen presenting cells is not likely to produce the desire antagonism.
  • Example VII By this Example it was demonstrated that, in addition to generating a T cell response in vitro (Example VII), the chimeric antibodies of the present invention could be used to generate a cellular response in vivo. Specifically, the following Example demonstrates the in vivo priming of PLP1 specific T cells by Ig-PLPI.
  • H-2 S mice Six to eight week old SJL mice (H-2 S ) were purchased from Harlan Sprague Dawley (Frederick, MD) and maintained in an animal facility for the duration of experiments.
  • mice were immunized subcutaneously in the foot pads and at the base of the limbs and tail with 50 mg of Ig- PLPl emulsified in a 200 ml mixture of 1:1 v/v PBS/CFA.
  • the results shown in Figure 7 are those obtained with 4 x 10 5 lymph node cells/well (7A) and 10 x 10 5 spleen cells/well (7B).
  • the activators PLP1 and PLP2 were used at 15 mg/mL and PPD was used at 5 mg/mL.
  • T cell activation was monitored using a proliferation assay comprising 3 H- thymidine incorporation.
  • lymph node and spleen cells were incubated for three days in 96-well round bottom plates, along with 100 ml of a single selected activator, at 4 and 10 x 10 5 cells/100 ml/well, respectively.
  • 1 mCi 3 H-thymidine was added per well, and the culture was continued for an additional 12-14 hours.
  • the cells were then harvested on glass fiber filters, and incorporated 3 H-thymidine was counted using the trace 96 program and an Inotech b counter.
  • a control media with no stimulator was included for each mouse and used as background.
  • FIGS 7A and 7B clearly show that, when Ig-PLPl was injected subcutaneously in the foot pads and at the base of the limbs and tail, a strong specific T cell response to the PLP1 peptide was induced. While there was some variation as to the strength of the reaction among the individual mice, the lymph node and spleen cells of each produced a significant response upon challenge with the PLP1 peptide. Interestingly there is a significant PLP1 specific response detected in the spleen, an organ that mostly filters and responds to systemic antigens.
  • mice show proliferation when the cells are stimulated with PLP2 peptide in vitro. Possibly, the fact that this peptide is presented by l-A s like PLP1 allows low affinity cells to bind and generate a response. In any case the results are consistent with those provided by the earlier Examples where it was shown that Ig-PLPl was efficient in presenting the peptide to T cells in vitro.
  • Ig-PLPl is capable of priming T cells in vivo and generates a potent immune response when exposed to the agonist PLP1 peptide.
  • This Example demonstrates that the administration of a peptide antagonist in the form of a chimeric antibody immunomodulating agent can substantially reduce the immune response generated by the endocytic presentation of an agonist ligand.
  • this Example demonstrates that co- administration of Ig-PLP-LR with Ig-PLPl significantly reduces the immune response to PLP1 peptide.
  • mice were co-immunized with mixtures of either 50 mg Ig-PLPl and 150 mg Ig-PLP-LR or 50 mg Ig-PLPl combined with 150 mg Ig-W.
  • individual mice from three groups (4 mice per group) were injected sc. as in Example X with a 200 ml mixture (PBS/CFA, 1:1 v/v) containing one of the following mixtures: 50 mg Ig-PLPl and 150 mg Ig-PLP-LR; 50 mg Ig-PLPl and 150 mg Ig-W; or Ig-PLPl and 100 mg PLP-LR peptide.
  • Splenic and lymph node T cell responses were analyzed at day 10 post immunization using the protocol set forth in Example X.
  • the lymph node cells were assayed at 4 x 10 5 cells/well and the spleen cells at 10 x 10 5 cells/well.
  • the agonist ligand was PLP1 at 15 mg/mL
  • Results for the lymph node and spleen cells shown in Figs. 8A and 8B respectively and summarized in Table 2 below, represent the mean ⁇ SD of triplicates after deduction of background cpm obtained with no agonist in the media.
  • Figures 8A and 8B show that, although Ig-PLPl was efficiently presented and induced a strong in vivo T cell response (Example X), it was possible to antagonize such a response by including Ig-PLP-LR in the mixture administered to mice.
  • mice given to the mice correspond to 1 nmole of Ig that contains 2 nmoles of PLP-LR peptide, while with a MW of 1,468 Daltons the 100 g of free PLP-LR peptide corresponds to 68 nmoles of peptide).
  • the failure of PLP-LR peptide to inhibit lg-PLPl mediated T cell activation coupled with the potency of Ig-PLP-LR in antagonizing Ig-PLPl T cell stimulation supports the belief that Ig-PLP-LR mediated in vivo antagonism is likely related to efficient presentation.
  • Example XII Induction of a T Cell Response to an Endocytically Presented Antagonist Previous Examples have shown that administration of chimeric antibodies comprising a agonist ligand can prime immune cells in vivo. It was also shown that administration of a chimeric antibody comprising an antagonist can reduce a subsequent response to challenge by an agonist ligand. This Example demonstrates that efficient presentation of an antagonist can prime immune cells in vivo and mount a strong response that could effect the reaction of the T cells to an agonist peptide. Specifically, mice co-injected with Ig-PLPl and Ig-PLP-LR develop a relatively high proliferative response to PLP-LR and practically no response to PLP1 peptide.
  • Lymph node and spleen cells were obtained in the same manner as set forth in Example X following co- administration of Ig-PLPl and Ig-PLP-LR. Proliferative responses in individual mice were also measured using the methods set out in the previous Example following in vitro stimulation with either free PLP1 peptide or PLP-LR peptide at 15 g/mL. The results of the assays using lymph node and spleen cells are detailed in Figures 9A and 9B respectively. As can be seen from Figure 9, both spleen and lymph nodes developed responses to the antagonist PLP-LR but not to the PLP agonist PLP1.
  • TCR engagement with PLP-LR-I-A S complexes i.e. MHC-PLP-LR complexes
  • MHC-PLP-LR complexes antagonizes T cells rather than stimulates them.
  • antagonism by Ig-PLP-LR may occur because efficient presentation of Ig-PLP-LR in endocytic vacuoles ensures significant levels of PLP-LR-I-A S complexes (antagonist complexes) are generated.
  • the amount of complexes on the cell surface is proportional to the amount of Ig-PLP-LR offered to the APCs.
  • both PLP-LR-I-A S and PLP1-I-A S are present on the surface of a given APC where an increase in the concentration of Ig-PLP-LR leads to higher number of PLP-LR-I-A S complexes.
  • approximately 3500 TCR have to be engaged in order for a T cell to be activated and that a given complex of MHC class ll-peptide complex serially engages approximately 200 TCRs.
  • a T cell is antagonized when TCR engagement with PLP-LR-I-A S complexes override engagement with the agonist PLP1-I-A S .
  • T cell antagonism is achieved by a higher frequency of serial triggering of TCR by PLP-LR-I-A S complexes. That is, the efficient uptake and processing of Ig-PLP-LR simply means that too many of the surface MHC complexes present the PLP-LR antagonist to allow the remaining surface complexes presenting the PLP1 agonist ligand to engage the number of TCRs to activate the T cell. Therefore, the T cells will not be activated as long as the antagonist is presented at a rate that ensures the activation concentration of MHC class ll-agonist complexes is not reached on the APC.
  • mice immunized with individual Ig-PLP chimeras or varying mixtures of Ig-PLPl and Ig-PLP-LR mice immunized with individual Ig-PLP chimeras or varying mixtures of Ig-PLPl and Ig-PLP-LR. It was observed that Ig-PLP-LR given alone to mice induced T cells which, like those induced by Ig-PLPl, cross-reacted with both PLP1 and PLP-LR peptides. Surprisingly, however, despite the cross-reactivity of the responses, when the chimeras were administered together they displayed a dose dependent antagonism on one another resulting in down-regulation of both T cell responses.
  • antigen specific T cells induced either by IG-PLP 1 or by IG-PLP-LR were refractory to down-regulation by peptide mixtures and proliferated significantly when they were in vitro stimulated simultaneously with both PLP1 and PLP-LR.
  • Lymph node and spleen cells were obtained in the same manner as set forth in Example X following co-administration of Ig-PLP 1 and Ig-PLP-LR.
  • Mice were injected with 50 g Ig-PLPl (10A), 50 g Ig-PLP-LR (10B), 100 g PLP1 (10C) or 100 g PLP-LR (10D) in CFA, and 10 days later the lymph node cells were in vitro stimulated with the indicated free peptides.
  • the stimulators PLP1, PLP-LR and PLP2 were used at the defined optimal concentration of 15 g/ml.
  • the data illustrated in figs 10A-10D indicate that Ig-PLPl, like PLP1 peptide, induced a specific T celi response to PLP1 peptide.
  • Ig-PLP-LR like PLP-LR peptide, induced a specific T cell response to PLP-LR peptide.
  • Neither the Ig chimera nor the free peptides induced T cells that significantly reacted with the negative control PLP2, a peptide that is also presented by l-A s class II molecules.
  • the response induced by Ig-PLPl cross-reacted with PLP-LR peptide, while the response induced by Ig-PLP-LR cross-reacted with PLP1.
  • PLP1 or free PLP-LR were not cross-reactive.
  • mice were injected with the indicated chimeras and 10 days later the lymph nodes cells were in vitro stimulated with free peptides, and assayed for proliferation by [ 3 H]th ⁇ midine incorporation as detailed above. The results are shown in Fig. 11.
  • the number preceding the Ig chimera label indicates the g amount injected per mouse.
  • the stimulators were PPD, 5 g/ml; PLP 1, PLP-LR, and PLP2 at 15 g/ml. Cells incubated without stimulator were used as background (BG).
  • mice were tested individually and triplicate wells were assayed for each stimulator. To standardize the results and eliminate intrinsic individual variability we expressed the results as relative proliferation estimated as follows: (mean test peptide cpm - mean BG cpm)/(mean PPD cpm • mean BG cpm). The indicated relative proliferation represents the mean ⁇ SD of 5 mice tested individually.
  • the mean cpms ⁇ SD obtained with PPD stimulation for the different groups of mice were as follows: 50 g Ig-PLPl :16,413 ⁇ 1330; 50 g Ig-PLP-LR: 11,224 ⁇ 3481; 50 g Ig-W: 11,513 ⁇ 1,572; 50 g Ig-
  • naive T cell all or most of the receptors on a single naive T cell must engage one type of peptide in order to expand).
  • Example XV Splenic Proliferative T Cell Responses of Mice Co-Immunized with Ig-PLPl and IG-PLP-LR As shown in Figure 12, spleen cells from the mice described in Example XIV were stimulated with PLP1 (filled bars) and PLP-LR ( hatched bars.) in triplicate wells and proliferation was measured as above. The results were standardized as above using PPD cpms obtained with lymph node T cells because the proliferation of spleen cells upon stimulation with PPD was minimal. The indicated relative proliferation represents the meant ⁇ SD of 5 individually tested mice.
  • IL-2 Production by Splenic Cells of Mice Co-Immunized With Ig-PLPl and Ig-PLP-LR To further investigate the opposing down-regulation among Ig-PLPl and Ig-PLP-LR, splenic antigen induced cytokine responses were measured in animals immunized with either a single or both Ig-chimeras. As shown in Fig. 13, spleen cells (1 X 10 6 per well) from the mice described in Example XIV were stimulated with PLP1 (filled bars) and PLP-LR (hatched bars) for 24 hours. Production of IL-2 (13A), INF (13B), and IL-4 (130 were measured as set forth below.
  • Biotinylated anti-cytokine antibodies were rat anti-mouse IL-2, JES6- 5H4; rat anti-mouse IL-4, BVD6-24G2; rat anti-mouse IFN , XMG 12; and rat anti-mouse IL- 10, JES5-16E3)
  • the 0D405 was measured on a Spec 340 counter (Molecular Devices) using SOH MAX PRO version 1.2.0 software. Graded amounts of recombinant mouse IL-2, IL-4, INF , and IL-10 were included in all experiments in order to construct standard curves. The concentration of cytokines in culture supematants was estimated by extrapolation from the linear portion of the standard curve.
  • BG Basal growth factor
  • T cells from Ig-PLPl immunized mice Upon in vitro stimulation with PLP1 peptide, T cells from Ig-PLPl immunized mice produced IL-2, INF , and small amounts of IL-4. However, stimulation of the same cells with PLP-LR yielded minimal IL-2 and undetectable INF or IL-4.
  • Spleen cells from Ig-PLP-LR immunized mice generated IL-2 but no IFN or IL-4 upon stimulation with PLP1 peptide.
  • PLP-LR peptide stimulation produced only a minimal IL-2 response. In mice immunized with equal amounts of Ig- PLP1 and Ig-PLP-LR all cytokine production was reduced to minimal or background levels upon stimulation with either peptide.
  • mice were immunized with Ig-PLPl or Ig-PLP-LR alone and assessed for proliferative T cell responses upon in vitro stimulation with varying mixtures of free PLP1 and PLP-LR peptides.
  • mice More particularly Mice (4 per group) were immunized with 50 g Ig-PLPl (14A and 14B) or 50 g Ig-PLP-LR (14C and 14D) in CFA, and 10 days later the lymph node (14A and 14C) and spleen (14B and 14D) cells were stimulated with the indicated peptides and assayed for [ 3 H]th ⁇ midine incorporation as above.
  • the number preceding the peptide label indicates the g/ml amount used for in vitro stimulation.
  • the specific proliferation was estimated by deducting the mean BG (obtained by incubating cells without stimulator) cpm from the test sample cpm. The indicated cpms represent the mean ⁇ SD of 4 individually tested mice. ND, not determined.
  • mice were immunized with Ig-PLP 1 or Ig-PLP-LR alone and assessed for cytokine responses upon in vitro stimulation with varying mixtures of free PLP1 and PLP-LR peptides. The results are shown in Figs. 15A and 15B.
  • Spleen cells from Ig-PLPl (15A) and Ig-PLP-LR (15B) immunized mice were stimulated with the indicated peptides and tested for IL-2 production by ELISA as in Example XVI.
  • the spleen cells used in these experiments were from the mice described in Example XVII.
  • the number preceding the name of the peptide represents the g/mi amount used for stimulation.
  • the indicated g/ml IL-2 values represent the mean d: SD of 4 individually tested mice.
  • IL-2 production was not decreased upon stimulation of spleen cells with varying mixtures of PLP1 and PLP-LR. To the contrary, in most cases of stimulation with peptide mixture IL-2 production was higher than in stimulation with a single peptide. Again these findings indicate that both agonist and antagonist peptides exert adverse reactions on one another and reveal an anti-parallel antagonism and a stringent control of TCR triggering at the level of naive T cells.
  • compositions may advantageously be used for the induction of tolerance in neonates and infants as demonstrated in the following Examples.
  • mice 10 mice per group
  • mice were injected with 100 g of affinity chromatography purified Ig-PLPl or Ig-W within 24 hours of birth and were induced for EAE with free PLP1 peptide at 7 weeks of age.
  • mice were scored daily for clinical signs as follows: 0, no clinical signs; 1, loss of tail tone; 2 , hind limb weakness; 3, hind limb paralysis; 4, forelimb paralysis; and 5, moribund or death.
  • Panel A shows the mean clinical score of all mice and panel B shows the mean score of the surviving animals only.
  • EAE was induced by subcutaneous injection in the foot pads and at the base of the limbs and tail with a 200 I IFA/PBS (1vol/1vol) solution containing 100 g free PLP1 peptide and 200 g M. tuberculosis H37Ra.
  • mice recipient of Ig-PLPl in saline at birth resisted the induction of EAE by free PLP1 peptide. Indeed, the clinical scores were much less severe in those mice than in animals recipient of Ig- W, the parental wild type Ig without any PLP peptide. In addition, contrary to those mice which received Ig-W, mice injected with Ig-PLPl showed no relapses (figure 16B).
  • Example XIX In Vivo Presentation of Ig-PLPl by Neonatal Thymic and Splenic Antigen Presenting Cells
  • cytokine responses were measured in neonatal mice. The data obtained is shown in Fig. 17.
  • mice 5 mice per group were injected with 100 g Ig-PLPl or Ig-W within 24 hours of birth. Two days later the mice were sacrificed, and pooled thymic (17A) and splenic (17B) cells were irradiated and used as APCs for stimulation of the PLP 1 -specific T cell hybridoma 4E3 as described above.
  • IL-2 production in the supernatant which was used as a measure of T cell activation was determined using the IL-2 dependent HT-2 cell line as described by
  • the administered Ig-PLPl was efficiently presented by neonatal APCs. Both thymic (17A) and splenic (17B) APCs from neonate recipients of IG-PLP1 activated a T cell hybridoma specific for PLP1 peptide without addition of erogenous antigen. APCs from neonate recipients of Ig-W were unable to activate the T cell hybridoma.
  • mice were injected intraperitoneal (i.p.)within 24 hours of birth with 100 g Ig-PLPl or Ig-W in saline. When the mice reached 7 weeks of age they were immunized with 100 g free PLP1 peptide in 200 I CFA/PBS (1vol/1vol) s.c. in the foot pads and at the base of the limbs and tail. Ten days later the mice were sacrificed, and (18A) the lymph node (
  • the mean splenic proliferative response was 3,300 ⁇ 3,400 for the Ig-PLPl recipient group and 14,892 ⁇ 4,769 for the Ig-W recipient group.
  • mice recipient of Ig-PLPl at the day of birth like those injected with Ig-W, developed equivalent adult lymph node T cell proliferative responses to PLP1 when they were immunized with free PLPI peptide in CFA (18A). However, the splenic proliferative response was markedly reduced in the mice recipient of Ig-PLPl (18B) thus indicating the inducement of tolerance. Neither group of mice showed a significant proliferative response to PLP2, a negative control peptide presented by l-A s class II molecules like PLP1.
  • cytokine responses were measured in were measured in mice inoculated with an immunomodulating agent at birth. The results are shown in Figs. 19A-19C.
  • lymph node cells (4 x 10 5 cells/well) from the mice described in Example XXI were stimulated in vitro with free PLP1 or PLP2 (15 g/ml) for 24 hours, and the production of IL-2 (19A), IL-4 (19B), and INF (19C) was measured by ELISPOT as described in Example XVI using Pharmingen anti-cytokine antibody pairs.
  • free PLP1 or PLP2 15 g/ml
  • mice Lymph node cells from mice recipient of Ig-W at birth produced, upon stimulation with PLP1, IL-2 but not INF or IL-4.
  • cells from mice recipient of Ig-PLPl were deviated and instead produced IL-4.
  • No cytokine production was observed upon stimulation with PLP2 peptide.
  • Example XXII Reduced INF Production by Splenic T Cells From Mice Injected With l ⁇ -PLPI at the Day of birth
  • spleen cells from the same mice were assayed for cytokine responses. The results are shown in Figs. 20A and 20B.
  • splenic cells (1 X 10 6 cells/well) from the mice were stimulated in vitro with free PLP1 or PLP2 (15 g/mi) for 24 hours, and the production of IL-2 (20A), IL-4 (20B), and INF (20C) in the supernatant was measured by ELISA using pairs of anti-cytokine antibodies from Pharmingen according to the manufacture's instructions (Example XVI).
  • the indicated amounts of cytokine represent the mean ⁇ SD of 8 individually tested mice.
  • mice inoculate with Ig-W produced IL-2 and INF .
  • cells from mice injected with Ig-PLPl produced IL-2 but failed to produce detectable levels of INF .
  • the negative control, PLP2 peptide failed to induce cytokine production.
  • Example XXI a group of neonates injected i.p. with 100 g of Ig-PLPl at birth were immunized with 100 g PLP1 peptide in CFA, as in Example XXI, and in vitro stimulation of splenic cells (1 x 10 6 cells/well) with free PLP1 peptide (15 g/ml) was carried out as described in Example XXI but in the presence of 100 units INF or IL- 12.
  • the indicated cpms for each mouse represent the mean ⁇ SD of triplicate wells.
  • addition of erogenous INF to splenic cells from the mice recipient of Ig-PLP 1 at birth restored the proliferative response.
  • IL-12 an inducer of INF (14), also restored the splenic proliferative response.
  • mice injected at birth with Ig-PLPl develop a lymph node T cell deviation and an unusual INF -mediated splenic anergy.
  • mice were induced for EAE with free PLP1 peptide they developed a mild monophasic disease without relapses.
  • an Ig based immunomodulating agent may endure for an extended period of time resulting in a continuous and slow release of the immunosuppressive factor, as may occur in the usual neonatal tolerization procedures using incomplete Freund's adjuvant with a conventional antigen. Consequently, delivery on Igs may allow one to circumvent the use of adjuvant to induce neonatal tolerance.
  • EAE mice were inoculated with aggregated Ig-PLPl. The results are shown in Fig. 22.
  • EAE was induced in a group of 10 mice with 100 ⁇ g of free PLP1 peptide as described above.
  • Soluble aggregated Ig-PLPl was prepared by heating a solution of Ig-PLPl for 15 minutes at 63°C and then centrifuging and filtering the resulting preparation to remove any insoluble aggregates that were formed during the process. The concentration of solubilized aggregates was then quantified using standard biochemical techniques.
  • mice When the clinical signs of EAE started to develop at day 10 post disease induction, the mice were injected with a saline solution containing 300 ⁇ g of the heat aggregated Ig-PLPl . A second and third injection of 300 ⁇ g of aggregated Ig-PLPl were given at days 14 and 17, respectively. Control treatments using aggregated Ig-W and soluble (unaggregated) Ig-PLPl were run in parallel. The grading of the clinical condition was done as described in Example XIX. In Fig. 22, the mice treated with aggregated Ig-PLPl are represented by dark circles while the controls are represented by light circles (soluble Ig-PLPl ) and triangles (aggregated Ig-W). The results clearly show that aggregated arrangements of the disclosed immunomodulating agents may be used to effectively reduce the symptoms associated with immune disorders.
  • compositions of the present invention advantageously induce anti-inflammatory cytokines
  • antigen presenting cells were exposed to aggregated lg-PLP1. The results are shown in Figs. 23A and 23B.
  • cytokines Three types of cells will be tested for production of cytokines upon incubation with aggregated Ig-peptide constructs. These include B cells, macrophages/monoc ⁇ tes, and dendritic cells.
  • B cells To obtain macrophages, adult SJL/J mice will be injected with thioglycolate and, at day 5 post injection, cells were harvested from the peritoneal cavity by extensive washing with ice cold sucrose (0.34 M ), and allowed to adhere to a plastic culture flask for 4 hours. Non- adherent cells were removed by vigorous pipetting. After an additional overnight culture, adherent cells will be collected by a cell scraper. Dendritic cells were purified from the spleen and enriched using standard biochemical techniques.
  • B cells were purified from the spleen by panning with a rat anti-kappa mab. For enrichment of resting B cells, macrophages, dendritic cells, and large (activated) B cells were removed using a sephadex G10-column.
  • the eluted cells were depleted of T lymphocytes by treatment with an anti-Thy 1.2 antibody and complement. FACS analysis is then performed to ensure that only preparations that are enriched to 90% or higher are stimulated with the aggregated constructs.
  • the enriched macrophages were tested for the production of IL-6 and IL-10 by ELISA using anti-cytokine antibody pairs from Pharmingen (San Diego, CA). The macrophages were used at 100 x 10 3 cells/well and the B cells and dendritic cells at 50 x 10 3 cells/well.
  • the cells (triplicate wells) were incubated with graded amounts of aggregated Ig-PLPl or a mouse myeloma IgM for 24 hours and the supernatant was used for measuring cytokine production.
  • the amount of cytokine in the supernatant was estimated by extrapolation on a standard curve constructed with known amounts of cytokine.
  • Figs. 23A and 23B show that the administration of aggregated Ig-PLPl enhances the production of anti- inflammatory cytokines such as IL-6 and 11-10. More particularly, Fig. 23A shows that exposure to aggregated constructs induces relatively high levels of IL-6 in macrophages (squares) while Fig. 23B shows that the same constructs enhances production of IL-10 in macrophages (squares) and dendritic cells (triangles). It should be appreciated that the production of such cytokines can inhibit the expression of MHC class II molecules and the upregulation of costimulatory molecules while favoring development of Th 2 type cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne une protéine de fusion destinée à atténuer les symptômes associés à une maladie auto-immune qui comprend une immunoglobuline ou une partie de celle-ci liée à un ou à plusieurs polypeptides antigéniques ou à leurs fragments, ladite immunoglobuline ou une partie de celle-ci étant capable de se lier à un récepteur de Fc et d'être accueillie par endocytose par une cellule présentatrice de l'antigène. Lors du traitement par endocytose, le ou les polypeptides antigéniques ou leurs fragments fournissent pour présentation plusieurs agonistes peptidiques de TCR à la surface de ladite cellule présentatrice de l'antigène. Ces polypeptides autoantigéniques peuvent comprendre au moins une partie de protéine basale myélinique ou au moins une partie de protéine protéolipidique. L'invention concerne aussi un procédé pour atténuer les symptômes associés à une maladie auto-immune chez un patient qui en éprouve le besoin, le procédé consistant à fournir une composition comprenant ladite protéine de fusion et à administrer une quantité thérapeutiquement efficace de ladite composition audit patient. Les maladies auto-immunes comprennent de manière non exclusive la sclérose en plaques, le lupus, la polyarthrite rhumatoïde, la sclérodermie, le diabète insulino-dépendant et la colite ulcéreuse. L'invention concerne aussi la présentation de plusieurs agonistes de TCR à la surface d'une cellule présentatrice de l'antigène professionnelle ou non professionnelle, ledit procédé consistant à fournir ladite protéine de fusion, à mettre ladite protéine de fusion en contact avec au moins un récepteur de Fc présent à la surface d'une cellule présentatrice de l'antigène professionnelle ou non professionnelle, grâce à quoi la protéine de fusion est internalisée par la cellule présentatrice de l'antigène, et à faire traiter par endocytose la protéine de fusion internalisée afin d'obtenir plusieurs agonistes peptidiques de TCR à la surface de ladite cellule présentatrice de l'antigène.
PCT/US1999/015225 1997-01-07 1999-07-06 Composes, compositions et procedes destines a la presentation endocytique de facteurs immunosuppresseurs WO2000001732A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU50908/99A AU5090899A (en) 1998-07-06 1999-07-06 Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
CA002331771A CA2331771A1 (fr) 1998-07-06 1999-07-06 Composes, compositions et procedes destines a la presentation endocytique de facteurs immunosuppresseurs
EP99935427A EP1093464A2 (fr) 1998-07-06 1999-07-06 Composes, compositions et procedes destines a la presentation endocytique de facteurs immunosuppresseurs
US11/612,773 US20070218053A1 (en) 1997-01-07 2006-12-19 Coupling of peripheral tolerance to endogenous il-10 promotes effective modulation of t cells and ameliorates autoimmune disease
US12/346,716 US20090280132A1 (en) 1997-01-07 2008-12-30 Coupling of peripheral tolerance to endogenous il-10 promotes effective modulation of t cells and ameliorates autoimmune disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11112398A 1998-07-06 1998-07-06
US09/111,123 1998-07-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11112398A Continuation-In-Part 1997-01-07 1998-07-06

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09/873,901 Continuation-In-Part US20020038002A1 (en) 1997-01-07 2001-06-04 Coupling of peripheral tolerance to endogenous IL-10 promotes effective modulation of T cells and ameliorates autoimmune disease
US11/612,773 Continuation-In-Part US20070218053A1 (en) 1997-01-07 2006-12-19 Coupling of peripheral tolerance to endogenous il-10 promotes effective modulation of t cells and ameliorates autoimmune disease

Publications (2)

Publication Number Publication Date
WO2000001732A2 true WO2000001732A2 (fr) 2000-01-13
WO2000001732A3 WO2000001732A3 (fr) 2000-04-27

Family

ID=22336745

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/015225 WO2000001732A2 (fr) 1997-01-07 1999-07-06 Composes, compositions et procedes destines a la presentation endocytique de facteurs immunosuppresseurs

Country Status (4)

Country Link
EP (1) EP1093464A2 (fr)
AU (1) AU5090899A (fr)
CA (1) CA2331771A1 (fr)
WO (1) WO2000001732A2 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016414A2 (fr) * 2000-08-22 2002-02-28 Micromet Ag Composition destinee a l'elimination des cellules b autoreactives
DE10109618A1 (de) * 2001-02-28 2002-09-12 Eppendorf Ag Verfahren zur Modifizierung von Zellen
WO2003068822A2 (fr) * 2002-02-13 2003-08-21 Micromet Ag Constructions (poly)peptidiques desimmunisees
WO2007107797A3 (fr) * 2006-03-22 2007-11-08 Immunobiology Ltd Composition et procédé pour la médiation de réponse immunitaire
WO2008015480A2 (fr) * 2006-08-01 2008-02-07 Immunobiology Limited Composition et procédé de modulation d'une réponse immunitaire
US7534440B2 (en) * 2001-05-01 2009-05-19 The Regents Of The University Of California Fusion molecules and methods for treatment of immune diseases
US10919963B2 (en) 2010-08-10 2021-02-16 École Polytechnique Fédérale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US11246943B2 (en) 2010-08-10 2022-02-15 École Polytechnique Fédérale De Lausanne (Epfl) Antigen-specific tolerance and compositions for induction of same
US12060414B2 (en) 2010-08-10 2024-08-13 École Polytechnique Fédérale De Lausanne (Epfl) Erythrocyte-binding therapeutics

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
AU2015233084B2 (en) 2014-02-21 2020-12-17 Anokion Sa Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
EP3638296A1 (fr) 2017-06-16 2020-04-22 The University Of Chicago Compositions et procédés d'induction d'une tolérance immunitaire

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998030706A1 (fr) * 1997-01-07 1998-07-16 The University Of Tennessee Research Corporation Composes, compositions et procedes pour la presentation endocytique de facteurs immunosuppresseurs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998030706A1 (fr) * 1997-01-07 1998-07-16 The University Of Tennessee Research Corporation Composes, compositions et procedes pour la presentation endocytique de facteurs immunosuppresseurs

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
B. MIN ET AL.: "Modulation in vivo of autoreactive T cells by a TcR antagonist Ig chimera." JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 99, no. 1, January 1997 (1997-01), page S183 XP002065436 *
B. MIN ET AL.: "Neonatal exposure to a self-peptide-immunoglobulin chimera circumvents the use of adjuvant and confers resistance to autoimmune disease by a novel mechanism involving interleukin 4 lymph node deviation and interferon gamma-mediated splenic anergy." THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 188, no. 11, 7 December 1998 (1998-12-07), pages 2007-2017, XP002131535 New York, NY, USA *
C. LIU ET AL.: "FcgammaRI-targeted fusion proteins result in efficient presentation by human monocytes and antagonist T cell epitopes." JOURNAL OF CLINICAL INVESTIGATION, vol. 98, no. 9, 1 November 1996 (1996-11-01), pages 2001-2007, XP002131533 New York, NY, USA *
K. LEGGE ET AL.: "Presentation of a T-cell receptor antagonist peptide by immunoglobulins ablates activation of T cells by a synthetic peptide or protein requiring endocytic processing." THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 185, no. 6, 17 March 1997 (1997-03-17), pages 1043-1053, XP002131534 New York, NY, USA *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7332168B2 (en) 2000-08-22 2008-02-19 Micromet Ag Composition for the elimination of autoreactive B-cells
WO2002016414A3 (fr) * 2000-08-22 2002-11-07 Micromet Ag Composition destinee a l'elimination des cellules b autoreactives
WO2002016414A2 (fr) * 2000-08-22 2002-02-28 Micromet Ag Composition destinee a l'elimination des cellules b autoreactives
DE10109618A1 (de) * 2001-02-28 2002-09-12 Eppendorf Ag Verfahren zur Modifizierung von Zellen
US7879324B2 (en) 2001-05-01 2011-02-01 The Regents Of The University Of California Fusion molecules and methods for treatment of immune diseases
US7534440B2 (en) * 2001-05-01 2009-05-19 The Regents Of The University Of California Fusion molecules and methods for treatment of immune diseases
US7323440B2 (en) 2002-02-13 2008-01-29 Micromet Ag De-immunized MOG (poly)peptide constructs
WO2003068822A2 (fr) * 2002-02-13 2003-08-21 Micromet Ag Constructions (poly)peptidiques desimmunisees
WO2003068822A3 (fr) * 2002-02-13 2004-03-04 Micromet Ag Constructions (poly)peptidiques desimmunisees
JP2009529906A (ja) * 2006-03-22 2009-08-27 イムノバイオロジー リミテッド 免疫応答を調節するための組成物および方法
WO2007107797A3 (fr) * 2006-03-22 2007-11-08 Immunobiology Ltd Composition et procédé pour la médiation de réponse immunitaire
CN103396495A (zh) * 2006-03-22 2013-11-20 免疫生物学有限公司 包含结合Fc受体的多肽和抗原性多肽的用于介导免疫应答的融合蛋白
WO2008015480A3 (fr) * 2006-08-01 2008-04-17 Immunobiology Ltd Composition et procédé de modulation d'une réponse immunitaire
WO2008015480A2 (fr) * 2006-08-01 2008-02-07 Immunobiology Limited Composition et procédé de modulation d'une réponse immunitaire
US10919963B2 (en) 2010-08-10 2021-02-16 École Polytechnique Fédérale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US11246943B2 (en) 2010-08-10 2022-02-15 École Polytechnique Fédérale De Lausanne (Epfl) Antigen-specific tolerance and compositions for induction of same
US11884721B2 (en) 2010-08-10 2024-01-30 École Polytechnique Fédérale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US12060414B2 (en) 2010-08-10 2024-08-13 École Polytechnique Fédérale De Lausanne (Epfl) Erythrocyte-binding therapeutics

Also Published As

Publication number Publication date
EP1093464A2 (fr) 2001-04-25
CA2331771A1 (fr) 2000-01-13
WO2000001732A3 (fr) 2000-04-27
AU5090899A (en) 2000-01-24

Similar Documents

Publication Publication Date Title
AU744885B2 (en) Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
EP1292621B1 (fr) Compositions pour le traitement des maladies auto-immunes
US20090181011A1 (en) Compounds, Compositions and Methods for the Endocytic Presentation of Immunosuppressive Factors
US20090280132A1 (en) Coupling of peripheral tolerance to endogenous il-10 promotes effective modulation of t cells and ameliorates autoimmune disease
US20070218053A1 (en) Coupling of peripheral tolerance to endogenous il-10 promotes effective modulation of t cells and ameliorates autoimmune disease
EP2254588B1 (fr) Procédés de préparation et composition de constructions de peptide utiles pour le traitement de la polyarthrite rhumatoïde
JP5570808B2 (ja) 併用療法におけるｃｄ８３の使用
WO2000001732A2 (fr) Composes, compositions et procedes destines a la presentation endocytique de facteurs immunosuppresseurs
AU2010303304A1 (en) Methods and compositions for amelioration of autoimmune disease using fusion proteins of anti-dendritic cell receptor antibody to peptide sequences
US20030103967A1 (en) Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
JP2021503276A (ja) 制御性ｔ細胞エピトープ
EP2989121B1 (fr) Méthodes de préparation et composition de constructions peptidiques utiles pour le traitement de la polyarthrite rhumatoïde
US20120082644A1 (en) Cytokines and neuroantigens for treatment of immune disorders
CA2404340C (fr) Procedes permettant d'inhiber la destruction tissulaire induite par les lymphocytes t autoreactifs
US6759385B1 (en) Methods to treat undesirable immune responses
US20210252137A1 (en) Aluminum based adjuvants for tolerogenic vaccination
CN117916257A (zh) 用于治疗自身免疫的工程化hla等位基因
US20160158330A1 (en) Methods of preparation and composition of peptide constructs useful for treatment of rheumatoid arthritis
Sitaraman Myasthenia gravis: Role of cytokines in disease and design of therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase in:

Ref document number: 2331771

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 09623728

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1999935427

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999935427

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 11612773

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 11612773

Country of ref document: US